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Abstract
Summary The scorecard summarises key indicators of
the burden of osteoporosis and its management in each
of the member states of the European Union. The
resulting scorecard elements were then assembled on a
single sheet to provide a unique overview of osteoporosis in
Europe.
Introduction The scorecard for osteoporosis in Europe
(SCOPE) is an independent project that seeks to raise
awareness of osteoporosis care in Europe. The aim of this
project was to develop a scorecard and background documents
to draw attention to gaps and inequalities in the provision of
primary and secondary prevention of fractures due to
osteoporosis.
Methods The SCOPE panel reviewed the information
available on osteoporosis and the resulting fractures for
each of the 27 countries of the European Union (EU27).
The information researched covered four domains:
background information (e.g. the burden of osteoporosis
and fractures), policy framework, service provision and
service uptake e.g. the proportion of men and women at
high risk that do not receive treatment (the treatment
gap).
Results There was a marked difference in fracture risk
among the EU27. Of concern was the marked heterogeneity
in the policy framework, service provision and service
uptake for osteoporotic fracture that bore little relation to
the fracture burden. For example, despite the wide
availability of treatments to prevent fractures, in the
majority of the EU27, only a minority of patients at high
risk receive treatment for osteoporosis even after their first
fracture. The elements of each domain in each country were
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scored and coded using a traffic light system (red, orange,
green) and used to synthesise a scorecard. The resulting
scorecard elements were then assembled on a single
sheet to provide a unique overview of osteoporosis in
Europe.
Conclusions The scorecard will enable healthcare pro-
fessionals and policy makers to assess their country’s
general approach to the disease and provide indicators to
inform future provision of healthcare.
Keywords SCOPE . Scorecard . Osteoporosis . Burden of
disease . Cost . European Union . Treatment uptake .
Treatment gap . Service provision . Service uptake . Policy
framework
SCOPE
Scorecard for osteoporosis in Europe
About SCOPE
The ScoreCard for OsteoPorosis in Europe (SCOPE) is an
independent project that seeks to raise awareness of
osteoporosis care in Europe. SCOPE permits an in depth
comparison of the quality of care of osteoporosis across the
27 member states of the European Union (EU27).
Osteoporosis is a complex disease that can be treated and
managed in a number of ways. Improvements in medication
and diagnostic techniques in the past 25 years have served to
reduce the risk of osteoporotic fractures. In Europe, however,
research has shown significant heterogeneity in the different
national approaches to the management of the disease.
The scorecard summarises key indicators of the burden
of osteoporosis and its management in each member state of
the European Union to draw attention to the disparities in
healthcare provision that can serve in the setting of
benchmarks to inform patients, healthcare providers and
policy makers in the EU.
The aim of this scorecard is to stimulate a balanced,
common and optimal approach to the management of
osteoporosis throughout the EU.
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A letter to all Europeans
The statistics are startling.
One in three women and at least one in six men will
suffer an osteoporotic fracture in their lifetime, and it is
estimated that more than ten million men and women
are at high risk of osteoporotic fractures in the European
Union.
Osteoporosis and the 3.5 million fractures it causes cost
the healthcare systems of Europe in excess of €39 billion
each year based on data for 2010. But numbers don’t tell
the full story. For the individuals who suffer fractures as a
result of the disease, the stories are personal. Pain,
disability, reduced mobility and long-term disability are
all too frequent. Additionally, fractures related to osteo-
porosis result in early death. About 43,000 deaths occur
each year in Europe as a direct consequence of hip or spine
fractures.
The primary purpose of the scorecard for osteoporo-
sis in Europe is to help individuals reduce their risk of
osteoporosis and to ensure that all Europeans have
access to the best diagnosis and treatment. Components
that are critical to achieving this goal include govern-
ment policy, access to assessment of risk and access to
medications. This scorecard allows Europeans to
measure how well their country is able to access these
elements through the publicly funded healthcare sys-
tems. It also provides a benchmark to measure future
progress.
Our research reveals that facilities and access to testing
for osteoporosis are far from adequate. Access to drug
treatment that can help prevent fractures varies markedly
from country to country; in some member states, individuals
with osteoporosis are restricted from accessing effective
treatment options. Less than half of women at high risk of
fracture are treated despite the high cost of fractures and the
availability of affordable medications.
Action is required. The national osteoporosis societies of
the International Osteoporosis Foundation are calling for a
Europe-wide strategy and parallel national strategies to
provide coordinated osteoporosis care and to reduce
debilitating fractures and their impact on individual lives
and the healthcare system. We welcome the opportunity to
partner with governments at the national and European level
to develop and implement these strategies. Together we can
improve the bone health of all in Europe.
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Introduction
The basis for SCOPE
SCOPE comprises an independent panel of experts that have
considered the information available on the burden of
osteoporosis and healthcare provision and uptake in the
EU27. SCOPE draws on independent research from twomajor
sources. The first was a series of regional audits of the
International Osteoporosis Foundation (IOF) [1–3]. This
information base was broadened and updated by IOF to inform
the SCOPE panel members through its outreach to over 30
national osteoporosis societies throughout Europe. The second
major resource was a comprehensive report undertaken by the
IOF and the Europian Federation of Pharmaceutical Industry
Associations (EFPIA) on the burden of osteoporosis in the
largest countries of theEU [4]. Thiswas subsequently extended
to all counties of the EU [5, 6] and made available to the panel.
From the information available, the panel developed
indicators of osteoporosis that could be applied to each
member state, categorised as:
Burden of disease—including the burden of osteopo-
rosis, fractures and forecasts for the future
Policy framework—such as the availability of public
health programmes
Service provision—including assessment and treat-
ments of osteoporosis
Service uptake—e.g. the proportion of men and
women at high risk that do not receive treatment
(treatment gap).
Comparisons of indicators across countries are often limited
by a lack of consistency of information retrieved across
countries. One of the strengths of the resource documents
considered by the panel is the consistency of the approach in
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documenting the burden of disease, wherever possible, by the
use of country-specific information. The Scorecard Panel and
the IOF invested substantial efforts to ensure that the European
audits were updated by means of a structured questionnaire
that was sent to all IOF national societies and key opinion
leaders in each country. Discrepancies and ambiguities were
resolved by correspondence. The panel recognised that
consistency does not necessarily equal accuracy and, where
information across countries is based only on opinion, this has
been highlighted. The questionnaire is available on the web
site of the IOF (http://www.iofbonehealth.org/).
For each domain, a synthesis was summarised and
tabular information provided for each member state which
appears in the body of the report. For key indicators, termed
scorecard elements, the information was scored and the
basis for the score allocation provided. For example, the
remaining lifetime risk of a hip fracture at the age of
50 years ranged from 7.0 to 25.1 % in women from the
different countries of the EU. Counties were categorised by
tertile of risk. High risk countries were colour coded red,
intermediate risk coded orange and low-risk countries coded
green. A similar ‘traffic light’ approach was applied to each
element in each domain. The resulting scorecard elements
were then assembled on a single sheet to provide a unique
overview of osteoporosis in Europe. It will enable
healthcare professionals and policy makers to assess their
country’s general approach to the disease and provide
indicators to inform future provision of healthcare.
Some caveats are appropriate in the interpretation of
scores. Green is not necessarily ‘good’ and red is not
necessarily ‘bad’. An example of the former is the
uptake of fracture liaison services. Whereas counties
coded green have up to 10 % of hospitals with such a
service, the panel would consider that 50 % or more
hospitals would be an appropriate target. Coding all
countries red would, however, not permit the compar-
ative performance of one country against another. Other
examples are highlighted in the text.
Osteoporosis
Osteoporosis is characterized by reduced bone mass
and disruption of bone architecture, resulting in
increased bone fragility and increased fracture risk
[7]. The publication of a World Health Organization
(WHO) report on the assessment of fracture risk and its
application to screening for postmenopausal osteoporo-
sis in 1994 provided diagnostic criteria for osteoporosis
based on the measurement of bone mineral density
(BMD) and recognised osteoporosis as an established
and well-defined disease that affected more than 75
million people in the United States, Europe and Japan
[8].
The diagnostic criterion for osteoporosis is based on
the measurement of BMD [9]. Bone mineral density is
most often described as a T score that describes the
number of SDs by which the BMD in an individual
differs from the mean value expected in young healthy
women. The operational definition of is defined as a
value for BMD 2.5 SD or more below the young female
adult mean (T score less than or equal to −2.5 SD).
BMD at the femoral neck is the international reference
standard [10]. The consequences of low BMD reside in
the fractures that arise. The relationship between BMD
and fracture is continuous in that the lower the BMD,
the higher the fracture risk [11].
Osteoporotic fractures
The most common fractures associated with osteoporo-
sis are those at the hip, spine, forearm and humerus but
many other fractures after the age of 50 years are
associated with low BMD and should be regarded as
osteoporotic [12]. These include fractures of the ribs,
tibia, pelvis and other femoral fractures. The causation
of fractures is not solely dependent on BMD but is
multifactorial. Many factors such as liability to falling,
age etc. contribute to the risk of fracture. Thus, not all
fragility fractures occur in individuals with a BMD
T score of −2.5 SD, and the terms osteoporosis, fragility
fracture and osteoporotic fractures have inherent ambi-
guities. For the purpose of this report, the term
osteoporosis is used in a generic sense rather than a
specific sense unless otherwise specified. For example
the ‘cost of osteoporosis’ refers to the cost of fractures
at sites associated with osteoporosis irrespective of the T
score.
The incidence of fragility fractures increases markedly
with age, though the rate of rise with age differs for
different fracture outcomes. For this reason, the
proportion of fractures at any site also varies with age.
For example, forearm fractures account for a greater
proportion at younger ages than in the elderly.
Conversely, hip fractures are rare at the age of 50 years
but become the predominant osteoporosis fracture from
the age of 75 years. In women, the median age for distal
forearm fractures is around 65 years and for hip fracture,
80 years. Thus, both the number of fractures and the
type of fracture are critically dependent on the age of
the populations at risk.
Hip fracture is the most serious osteoporotic fracture.
Hip fracture is painful and nearly always necessitates
hospitalisation and surgical intervention. Up to 20 % of
patients die in the first year following hip fracture,
mostly as a result of serious underlying medical
conditions [13], and less than half of survivors regain
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the level of function that they had prior to the hip
fracture [14]. Thus, not all deaths associated with hip
fracture are due to the hip fracture event and it is
estimated that approximately 30 % of deaths are
causally related. When this is taken into account, hip
fracture causes more deaths than road traffic accidents in
Sweden and about the same number as those caused by
breast cancer [15].
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Chapter 1. Burden of disease
1a Economic framework
Domain
Burden of disease—background information
Background and aims
Cost of illness studies provide no direct guidance on how
resources should be allocated, but may provide relevant
information concerning the consequences of a disease that
may inform policy. Such data may aid decisions concerning
societal resource allocation for research, development, and
funding of new treatments. Results from cost-of-illness
studies can also be utilised to assess the long-term
consequences and value of medical progress.
The objective of this background section is to
estimate the current cost of osteoporotic fracture in
the countries of the European Union set against the
wealth of the nation and the healthcare spend of that
wealth. A more detailed consideration of the cost is
given in Chapter 1b.
Methods
Direct costs of fractures in men and women from the
EU27 aged 50 years or more were expressed as a
proportion of total health care spending in the respective
Table 1 Cost of osteoporotic fractures in relation to the population and health care spending (2010)
Country Population
(000)
Health care spending
(€000,000)
Health care spending
(% GDP)
Health care spending
(€/capita)
Fracture cost (% health
care spending)
Austria 8,392 31,000 10.2 3,741 2.5
Belgium 10,712 42,000 9.9 3,903 1.5
Bulgaria 7,493 2,700 7.2 354 1.6
Cyprus 1,103 1,000 6.2 937 5.2
Czech Republic 10,493 11,000 6.9 1,087 2.2
Denmark 5,551 26,000 10.8 4,759 4.0
Estonia 1,339 1,000 5.2 747 3.0
Finland 5,365 18,000 8.2 3,263 2.2
France 62,634 227,000 11.0 3,617 2.1
Germany 82,056 281,000 10.6 3,418 3.2
Greece 11,358 24,000 9.5 2,126 2.9
Hungary 9,985 7,000 8.3 709 3.6
Ireland 4,470 15,000 7.5 3,399 1.5
Italy 60,098 148,000 9.0 2,461 4.7
Latvia 2,252 1,000 6.6 520 3.2
Lithuania 3,325 2,000 6.2 546 2.6
Luxembourg 506 3,000 7.3 6,235 0.7
Malta 416 500 8.4 1,108 3.8
Netherlands 16,610 64,000 9.4 3,829 1.3
Poland 38,276 25,000 6.2 660 2.4
Portugal 10,676 19,000 10.2 1,826 3.0
Romania 21,486 7,000 4.5 309 2.0
Slovakia 5,463 3,000 7.1 1,092 3.6
Slovenia 2,028 6,000 8.4 1,485 0.9
Spain 45,317 102,000 8.4 2,247 2.8
Sweden 9,294 34,000 9.2 3,709 4.3
UK 61,899 159,000 8.2 2,564 3.4
EU27 498,597 1,260,000 2,528 3.0
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country [1] and as the cost per capita of the general
population [2, 3].
Results
Health care spending varied markedly between countries,
ranging from €500 million in Malta to €281 billion in
Germany (Table 1). The total spend on healthcare in the
European Union amounted to €1,260 billion, with the cost
of osteoporotic fractures representing approximately 3 %
of the healthcare spend (€37.4 billion in 2010). This
clearly demonstrates a substantial impact on the present
healthcare budget
The share of health care spending allocated to osteopo-
rosis varied across countries, ranging from 0.7 % in
Luxembourg to 5.2 % in Cyprus (Fig. 1). As might be
expected there was a significant but modest relationship
between the amount spent on osteoporosis, GDP and the
incidence of osteoporotic fractures.
The estimated cost of osteoporosis may be compared to
the cost of other diseases. However, given that the EU27 is
a relatively new construct, few directly comparable studies
exist. Furthermore, methodological differences render some
studies difficult to compare. However, a few studies are
available conducted in a similar geographic area with
comparable methodology.
In a report issued by the European Brain Council, the
yearly societal costs for a number of brain disorders in the
EU27 were estimated at €105 billion for dementia, €43.5
billion for headache, €14.6 billion for multiple sclerosis,
and €13.9 billion for Parkinson’s disease [4].
The cost of coronary heart disease and cerebrovascular
disease in the European Union (25 countries) has been
estimated at approximately €45 billion and €34 billion,
respectively, at 2003 prices [4]. The cost of epilepsy in the
European Union (25 countries) has been estimated at €15.5
billion at 2004 prices. Healthcare costs comprised 18 % of
costs, whereas direct medical costs and productivity losses
represented 27 % and 55 %, respectively [5]. Thus, in
relation to other common non-communicable diseases
osteoporosis has major economic consequences for society.
Score allocation
None—not a score card element
Comment
It should be noted that not all fracture-related costs come
from the countries’ healthcare budgets (e.g. long-term care
and variable reimbursement policies). Data on healthcare
spending are for 2006.
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1b Healthcare cost of osteoporotic fractures
Domain
Burden of disease—background information
Background and aims
Cost of illness studies can take on a societal perspective (includes
all cost carried directly or indirectly by society) or a payer
perspective (usually includes all costs carried by the healthcare
Fig. 1 Proportion (%) of the total direct healthcare spend in the EU27
countries allocated to osteoporotic fractures [3]
Arch Osteoporos (2013) 8:144 Page 7 of 63, 144
and social system). Both play an important role in the
understanding of disease implications and may aid decisions
concerning societal resource allocation for research, develop-
ment, and funding of new treatments. Results from cost of illness
studies can also be utilised to assess the value ofmedical progress.
The main objective of this section is to provide detail on
the current cost of osteoporotic fractures in the countries of
the European Union.
Methods
The cost of osteoporotic fractures was first determinedwithout
intangible costs (i.e. the monetary value of QALYs lost due to
death and disability) [1]. Costs of fracture-related productivity
losses were not included because they are only incurred in
patients below retirement age—median age 60 years in Europe
[2]—and are less than 1 % of hip fracture cost in Sweden [3].
Empirical but incomplete cost estimates were available
for Austria, Belgium, Czech Republic, Denmark, Finland,
Germany, Ireland, Italy, Netherlands, Portugal Slovenia,
Sweden and the UK. For countries where fracture costs
were not found, the costs were imputed from the nearest
country available by adjusting for differences in healthcare
price levels between the relevant countries.
Costs were divided into the direct cost of fractures in 2010,
the ongoing cost in 2010 of fractures occurring before 2010
(‘long-term disability’), and the cost of intervention for
osteoporosis. It was conservatively assumed that fractures
other than those at the hip did not incur any longer-term costs
after the first year. Hip fracture costs in the second and
following years after the event were based on the proportion of
patients that become dependent in the long-term.
The health burden of osteoporosis was additionally
measured in terms QALYs lost. The QALY is a multi-
dimensional outcome measure that incorporates both the
quality (health related) and quantity (length) of life. The
value of a QALY was set at value of 2× GDP per capita [4].
Results
The direct cost of osteoporosis in the EU27 from the
fractures that occurred in 2010 was €24.6 billion (Table 2).
Table 2 Cost of osteoporosis in the EU27 in 2010 (€ million, 2010) [1]
Country Incident
fractures
Long-term
disability
Intervention Total Cost per capita (€) QALYs lost (€m)
Austria 540 229 30 799 95 1 903
Belgium 419 157 29 606 57 1 734
Bulgaria 30 11 1 42 6 118
Cyprus 34 7 12 52 47 78
Czech Republic 165 56 53 273 26 630
Denmark 718 300 37 1,055 190 1 704
Estonia 22 7 1 30 22 59
Finland 269 104 10 383 71 829
France 3,179 1,329 346 4,853 77 8 309
Germany 6,617 2,055 336 9,008 110 14 927
Greece 488 102 91 680 60 1 263
Hungary 127 30 40 197 20 464
Ireland 125 62 35 223 50 426
Italy 4,269 2,402 361 7,032 117 8 771
Latvia 29 7 2 38 17 72
Lithuania 32 12 3 47 14 81
Luxembourg 15 4 2 22 43 148
Malta 11 4 2 17 41 24
Netherlands 360 434 29 824 50 1 863
Poland 355 162 76 593 16 991
Portugal 293 264 20 577 54 580
Romania 88 35 7 129 6 339
Slovakia 76 19 11 107 20 283
Slovenia 36 13 7 56 28 168
Spain 1,372 1,055 414 2,842 63 3 271
Sweden 927 529 29 1,486 160 2 666
UK 3,977 1,328 103 5,408 87 8 698
EU27 24,574 10,718 2,087 37,378 75 57 243
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To this is added the ongoing cost in 2010 incurred by
fractures that occurred before 2010 which amounted to
€10.7 billion (long-term disability). The cost of pharmaco-
logical intervention (assessment and treatment) was €2.1
billion. Thus, the total direct cost in the EU27 (excluding
the value of QALYs lost) amounted to €37.4 billion in 2010.
First year, subsequent year, and pharmacological costs
accounted for 66, 29 and 5 % of the costs respectively.
Whilst the proportion of costs for pharmacological
intervention to total costs was low on average, some inter-
country variation was observed: the lowest proportion of costs
attributable to intervention was observed in Sweden (2%) and
the highest costs in Hungary (4.7 %). Hip fractures were
estimated to account for 54 % of the total costs, other fractures
39 %, vertebral fractures 5 %, and forearm fractures 2 %.
On average, the direct cost of osteoporotic fractures was
€75 for each individual in the EU27. There was a large
variation in the ‘osteoporosis tax’ (cost per capita) which
was highest in Denmark (€188/person) and Sweden (€159)
and lowest in Bulgaria (€6) and Romania (€6). The
heterogeneity of this cost is in part related to the incidence
of fracture (r=0.67, p=0.001) and the healthcare spend per
capita (r=0.63, p=0.004).
The cost of QALYs lost in the EU27 was substantial
amounting to €57.2 billion, giving a total cost of €94.6
billion in 2010. Intervention costs amounted to 2 % of the
total cost (Fig. 2) and 5 % of the direct costs.
Score allocation
None—not a score card element
Comment
There are few directly comparable studies in other non-
communicable diseases that exist.
For coronary heart disease, healthcare costs, produc-
tivity losses, and informal care comprised 51, 34 and
15 %, respectively. Costs for pharmacological treatment
accounted for 12 % of the total cost, substantially higher
than that for osteoporosis. For cerebrovascular disease,
healthcare costs, productivity losses, and informal care
comprised 61, 18 and 21 %, respectively. The cost for
pharmacological treatment accounted for 3 % of the total
cost for cerebrovascular disease [5], somewhat lower
than that for osteoporosis.
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1c Men and women with osteoporosis
Domain
Burden of disease—background information
Background and aims
Osteoporosis is diagnosed using dual-energy X-ray absorp-
tiometry (DXA) to measure bone mineral density (BMD).
The diagnostic reference site is the femoral neck using the
NHANES III reference data [1]. Osteoporosis is diagnosed
when the BMD measured at the femoral neck is more than
2.5 standard deviations below the average value of the
young white female population [2]. The aim of this
background information was to document the burden of
osteoporosis as judged by densitometric criteria.
Methods
Accurate estimates of the prevalence of osteoporosis require
country-specific data on the distribution of femoral neck
BMD. However, large population-based reference data are
lacking in the EU27 countries. For the purposes of thisFig. 2 Components (%) of the cost of osteoporosis and fractures [1]
Arch Osteoporos (2013) 8:144 Page 9 of 63, 144
report, it is assumed that the mean femoral neck BMD is
similar across EU countries at the age of 50 years as is the
rate of bone loss at the femoral neck with age. The same
assumptions have been used elsewhere [3–8]. On this basis,
the prevalence of osteoporosis was calculated from the age-
and sex-specific BMD in the NHANES III study. These
prevalence estimates were then applied to the population
demography in each EU country [9].
Results
In 2010, there were approximately 27.6 million men and
women with osteoporosis in the EU27, of which 5,500,000
were men and 22,100,000 were women, i.e. there were four
times asmanywomenwith osteoporosis as there weremen.Of
all member states, Germany was estimated to have the highest
number of individuals with osteoporosis with approximately 1
million osteoporotic men and 4 million osteoporotic women.
Overall, the prevalence of osteoporosis was 6.6 and 22.1 % in
men and women aged 50 years or more (Table 3). In men over
the age of 50 years, the prevalence of osteoporosis varied from
5.9 (Poland) to 7.2 % (Luxembourg). In women, the
prevalence ranged from 19.1 (Cyprus) to 23.5 % (France).
The prevalence of osteoporosis in the entire EU27
population (i.e. all ages) was 5.5 % and ranged from 3.7 %
in Cyprus and Ireland to 6.3 % in Italy (Fig. 3).
Score allocation
None—not a score card element
Comment
Although BMD is a strong predictor of fracture risk [10,
11], the prevalence of osteoporosis is not used as a score
Table 3 Estimated number of men and women with osteoporosis, prevalence in population over 50 years, and prevalence in the total population,
2010 [9]
Country Men with
osteoporosis
Women with
osteoporosis
Men and
women with
osteoporosis
Prevalence in male
population aged
50 or more (%)
Prevalence in female
population aged
50 or more (%)
Prevalence in total
population (%)
Austria 89,862 368,685 458,547 6.5 22.2 5.5
Belgium 120,695 476,875 597,570 6.6 22.4 5.6
Bulgaria 81,482 336,425 417,907 6.4 20.9 5.6
Cyprus 9,263 31,032 40,295 6.2 19.3 3.7
Czech Republic 103,114 425,944 529,058 6.0 20.4 5.0
Denmark 61,456 221,912 283,368 6.5 21.1 5.1
Estonia 11,642 65,789 77,431 6.2 22.2 5.8
Finland 61,054 243,399 304,453 6.4 21.5 5.7
France 691,112 2,784,198 3,475,310 6.7 22.5 5.5
Germany 1,006,652 4,017,260 5,023,912 6.6 22.6 6.1
Greece 135,202 507,505 642,707 6.9 22.3 5.7
Hungary 94,949 452,158 547,107 6.2 21.1 5.5
Ireland 37,127 129,309 166,436 6.2 20.0 3.7
Italy 749,237 3,042,794 3,792,031 6.9 23.4 6.3
Latvia 19,210 111,236 130,446 6.1 22.3 5.8
Lithuania 27,136 148,375 175,511 6.1 21.7 5.3
Luxembourg 4,541 17,422 21,963 6.1 21.0 4.3
Malta 4,190 16,074 20,264 5.9 19.8 4.9
Netherlands 175,244 643,258 818,502 6.3 20.8 4.9
Poland 338,756 1,509,772 1,848,528 5.8 20.1 4.8
Portugal 117,738 475,882 593,620 6.7 22.0 5.6
Romania 198,065 835,885 1,033,950 6.2 20.5 4.8
Slovakia 42,726 188,911 231,637 5.7 19.4 4.2
Slovenia 20,543 89,489 110,032 6.0 21.5 5.4
Spain 496,368 1,952,987 2,449,355 6.8 22.6 5.4
Sweden 113,722 409,373 523,095 6.9 22.4 5.6
UK 679,424 2,527,331 3,206,755 6.7 21.9 5.2
EU27 5,490,510 22,029,280 27,519,790 6.6 22.1 5.5
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card element because the relationship of osteoporosis to
fracture risk varies by age and between countries [12]. For
this reason, fracture risk is the preferred metric.
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1d Epidemiology of hip fracture
Domain
Burden of disease—scorecard element
Background and aims
Fracture incidence is poorly documented in the EU. The
fracture incidence that has been best evaluated is hip
fracture. Hip fractures account for the majority of health
care expenditure, mortality and morbidity and can be used
as a proxy for osteoporosis. There is a marked difference in
the incidence of hip fracture worldwide and probably in
other osteoporotic fractures [1]. Indeed, the difference in
incidence between countries within Europe is greater than
the differences in incidence between sexes within a country
[2, 3]. The EU comprises countries with some of the highest
hip fracture rates, but the documentation of the size of the
problem and the quality of data vary between countries.
The aim of this scorecard element was to summarise the
information base available for the incidence of hip fracture.
Methods
Studies on hip fracture risk were identified from 1950 to
November 2011 by aMedline OVID search. Evaluable studies
in each country were reviewed for quality and representative-
ness and a study (studies) chosen to represent that country.
Age-specific incidence rates were age-standardised to the
world population in 2010 in men and in women [1].
Results
National data on hip fracture rates were identified in 17
member states (Table 4). No data were available for four
countries (Bulgaria, Cyprus, Latvia, and Luxembourg). In the
remaining six countries, regional estimates were identified.
For Estonia and Slovenia data were available in women only.
As expected, hip fracture rates were higher in women than
in men with a female/male ratio that ranged from 1.4
Fig. 3 Components (%) of the cost of osteoporosis and fractures [1]
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(Romania) to 2.7 (Portugal). There was a nearly three-fold
range of hip fracture rates throughout the EU from
198/100,000 (Romania) to 574/100,000 (Denmark). Thus,
the international variation between countries was greater than
the differences between men and women within countries.
Score criteria
The age-standardised incidence was ranked. Women were
chosen since fracture rates are more robust and it permitted
the inclusion of Estonia and Slovenia for which no data
were available in men. The criteria for categorisation were
chosen as described in Table 5.
Score allocation
The ranked incidence is shown in Fig. 4 and colour coded
by category.
Comment
On an international scale, all countries were at moderate
or high risk (150–250/100,000 and >250/100,000,
respectively) [1].
Reasons for the large variation in fracture risk between
countries are speculative, but, ecological studies have
shown a weak but significant relationship between hip
fracture risk and latitude and socio-economic prosperity [4].
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Table 4 Information available on age-standardised (2010) hip fracture
rates (/100,000/year) in countries of the European Union [1]
Year Sample Incidence F/M
Women Men
Austria 2001–5 National 501 246 2.0
Belgium 2005–7 National 356 169 2.1
Bulgaria
Cyprus
Czech Republic 2008–9 National 374 211 1.8
Denmark 2004 National 574 290 2.0
Estonia 1991–4 Regional 225 – –
Finland 2000–5 National 293 180 1.6
France 2004 National 291 126 2.3
Germany 2003–4 National 346 166 2.1
Greece 1986–92 Regional 326 158 2.1
Hungary 1999–03 National 367 206 1.8
Ireland 2008–10 National 406 191 2.1
Italy 2007 National 334 140 2.4
Latvia
Lithuania 2010 National 270 156 1.7
Luxembourg
Malta 2003–7 National 355 160 2.2
Netherlands 2005 National 249 121 2.1
Poland 2008 Regional 224 133 1.7
Portugal 2000–2 National 268 98 2.7
Romania 2005–9 National 198 142 1.4
Slovakia 2007 National 401 263 1.5
Slovenia 2003 National 349 – –
Spain 1984–91 Regional 228 92 2.5
Sweden 1991 Regional 539 247 2.2
UK 1992–3 Regional 349 140 2.5
Table 5 Criteria for allocating scores
Fig. 4 Annual incidence of hip fracture in women from countries of
the EU age-standardised to the world population for 2010 [1]
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1e Number of fragility fractures
Domain
Burden of disease—scorecard element
Background and aims
The most obvious and serious effect of osteoporosis is the
fractures that occur as a consequence of increased bone
fragility. This section determines the number of fractures
associated with bone fragility in the EU27.
Methods
The fractures of interest include those at the hip, spine and
forearm as well as osteoporotic fractures at other vulnerable
sites (humerus, ribs, tibia, pelvis and other femoral
fractures) grouped as other fractures. Information on the
incidence of osteoporotic fractures varies between the
countries of the EU27. In general, reports on hip fracture
incidence are more complete than for fractures at other sites
(see Chapter 1d).
The risk of hip fracture was taken from a systematic
review of hip fracture incidence [1]. For the EU27
countries with incomplete information, incidence was
taken from the nearest country where hip fracture
incidence was available [2]. Where the incidence of
fractures other than the hip was not available, the
incidence was imputed from the hip fracture incidence
in the relevant country, using the relationship between
hip fracture incidence and incidence of fracture in other
sites in Sweden [3].
The number of fractures in each country for each fracture
site was computed from the age- and sex-specific estimates
of incidence and population demography for 2010 [4].
Crude incidence in each country was expressed as the
number of fragility fractures per 1000 of the population
aged 50 years or more.
Results
There were estimated to be 3.5 million new fragility fractures
in the EU in 2010—equivalent to 9,556 fractures/day (or
390/h) (Table 6). Almost twice as many fractures occurred in
women compared to men. Hip, vertebral, forearm and other
fractures accounted for 18, 15, 16 and 51 % of all fractures,
respectively.
The number of incident fractures per country is shown in
Table 7. Germany had the highest number of fractures for
Table 6 Estimated number of incident fractures in the EU27 by site,
2010 [2]
Men Women Men and
women
Hip fractures 168,511 446,806 615,317
Vertebral fractures 188,867 327,397 516,264
Forearm fractures 96,307 464,273 560,580
Other fractures 740,590 1,059,307 1,799,897
All fractures 1,194,275 2,297,783 3,492,058
Table 7 The number of new fragility fractures in 2010 in men and
women by country, the population at risk (men and women aged
50 years or more) and the crude incidence (/1000 of the population) [2]
Country New fractures Population
at risk (000)
Rate/1,000
Austria 86,536 3,041 28.5
Belgium 79,893 3,959 20.2
Bulgaria 38,198 2,876 13.3
Cyprus 5,129 311 16.5
Czech Republic 72,195 3,802 19.0
Denmark 66,358 2,003 33.1
Estonia 8,688 485 17.9
Finland 36,405 2,090 17.4
France 376,774 22,645 16.6
Germany 724,774 33,010 22.0
Greece 85,518 4,236 20.2
Hungary 102,457 3,683 27.8
Ireland 18,085 1,246 14.5
Italy 465,400 23,788 19.6
Latvia 14,305 812 17.6
Lithuania 15,074 1,127 13.4
Luxembourg 2700 158 17.1
Malta 2641 152 17.4
Netherlands 75,947 5,893 12.9
Poland 167,664 13,350 12.6
Portugal 51,821 3,922 13.2
Romania 94,282 7,289 12.9
Slovakia 38,634 1,730 22.3
Slovenia 15,510 759 20.4
Spain 204,151 15,905 12.8
Sweden 107,046 3,489 30.7
United Kingdom 535,873 21,636 24.8
EU27 3,492,058 183,397 19.0
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all fracture types in both men and women—approximately
724 000 incident fractures in total—predominately
reflecting a large population size and comparatively high
fracture incidence. Malta and Luxembourg had the lowest
number of fractures for all types—(less than 3 000 incident
fractures in each country), reflecting small population sizes.
When fracture numbers were expressed as a rate of the
population at risk, there was a greater than two-fold range in
risk that varied from 12.6/1000 in Poland to 33.1/1000 in
Denmark.
In addition to pain and disability, some osteoporotic fractures
are associated with premature mortality. About 30 % of deaths
after a hip or clinical spine fracture can be attributed to the
fracture event [5–7]. In theEU, therewere estimated to be 43,000
deaths causally related to in 2010. Approximately 50 % of
fracture-related deaths in womenwere due to hip fractures, 28%
to clinical vertebral and 22 % to other fractures. Corresponding
proportions for men were 47, 39 and 14 %, respectively.
Fracture-related deaths by country are shown in Fig. 5. Note that
the variability in death rates is more a reflection of the variable
incidence of fractures rather than in standards of care.
Score criteria
The number of fragility fractures in men and women
combined in 2010 expressed/1,000 of the population aged
50 years or more was categorised approximately by tertiles
as given in Table 8.
Score allocation
Countries, ranked and categorised by risk, are shown in Fig. 6.
The variation between countries reflects both the fracture risk
and the distribution of age and sex in each country.
Comment
The calculation of fracture numbers from hip fracture
rates assumes that the ratios between age- and sex-
specific incidence of hip fracture and fractures of other
sites found in Sweden are similar in other countries.
This assumption has been shown to hold true for the
countries where this has been tested [3, 8].
These estimates do not include individuals who in 2010
were suffering the consequences of fractures sustained in
previous years.
There are important data gaps in the documentation of
the fracture burden between member states which form the
component of a further scorecard element (Chapter 2a).
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1f Lifetime hip fracture probability
Domain
Burden of disease—scorecard element
Background and aims
The most serious consequence of osteoporosis in terms of
morbidity, mortality and health care expenditure is hip
fracture. In the EU, for example, hip fractures comprise
only 17 % of the total number of fragility fractures but
account for 54 % of the direct costs and 49 % of deaths due
to fracture [1]. The likelihood of hip fracture can be
expressed as fracture probability from a given age over a
given time interval (e.g. 10 years).
The aim of this element is to provide estimates of the
remaining lifetime probability of hip fracture in men and
women at the age of 50 and 70 years.
Methods
Hip fracture probability was computed taking both the risk
of fracture and the risk of death into account [2]. The risk of
hip fracture was taken from a systematic review of hip
fracture incidence [3]. Where possible, the incidence of hip
fracture was determined in men and women using 5-year
age categories. Where 5-year age intervals were not
available, 10 year intervals were used (intervals of greater
than 10 years were an exclusion criterion). Mortality
statistics of the WHO were used in 5 or 10 year age
intervals for the year 2010 [4]. The remaining lifetime
probabilities were calculated in men and women from the
age of 50 and 70 years.
Results
Empirical data on hip fracture rates were available for 21 of
the 27 EU member states in men and women. No data were
available for men from Estonia and Slovenia. Hip fracture
incidence is not documented in Bulgaria, Cyprus, Latvia or
Luxembourg.
The average remaining lifetime probability of hip fracture in
women at the age of 50 years ranged from 7.0 % (Romania) to
25.1 % (Sweden). Thus, there was approximately a three-fold
range of lifetime probabilities between countries (Table 9).
Table 9 Remaining lifetime probability of hip fracture (%) at the ages
of 50 and 70 years in men and women by country, 2010 [3]
Country Lifetime probability (%)
At age 50 years At age 70 years
Men Women Men Women
Austria 8.3 19.7 8.8 20.7
Belgium 7.8 18.2 8.3 18.9
Bulgaria – – – –
Cyprus – – – –
Czech Republic 6.9 14.8 7.5 15.6
Denmark 10.6 22.1 11.1 23.6
Estonia – 23.3 – 21.1
Finland 5.8 12.4 6.1 12.8
France 5.6 18.4 6.3 19.4
Germany 5.3 14.2 5.6 15.0
Greece 8.0 15.8 8.6 15.2
Hungary 4.1 10.6 5.2 12.0
Ireland 7.8 18.2 8.0 18.7
Italy 7.7 19.2 7.8 19.3
Latvia – – – –
Lithuania 4.4 11.3 5.3 11.9
Luxembourg – – – –
Malta 5.8 14.2 5.8 14.2
Netherlands 5.4 12.5 5.6 12.8
Poland 4.0 9.7 3.9 10.1
Portugal 4.8 14.4 5.3 14.9
Romania 3.8 7.0 3.7 7.2
Slovakia 9.5 20.3 9.9 20.3
Slovenia – 11.6 – 12.0
Spain 4.0 12.1 4.3 12.6
Sweden 10.9 25.1 11.0 25.4
United Kingdom 4.8 13.8 5.0 14.6
– denotes no data
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Probabilities of hip fracture were approximately two-fold
lower in men than in women. In men, hip fracture probability
at the age of 50 years ranged from 3.8 % (Romania) to 10.9 %
(Sweden). There was a close correlation between hip fracture
probability inmen andwomen so that in those countries where
fracture probability was high in women, so too was it high in
men (Fig. 7). In Sweden, which had the highest hip fracture
probabilities, the hip fracture risk in men (10.9 %) was higher
than the hip fracture probability in women from Hungary,
Poland or Romania.
Score criteria
The remaining lifetime probability of hip fracture at the age
of 50 years was ranked. Women were chosen since it
permitted the inclusion of Estonia and Slovenia for which
no data were available in men. The criteria for
categorisation are shown in Table 10.
Score allocation
The ranked incidence is shown in Fig. 8 and colour coded
by category.
Comment
Hip fracture probabilities from the age of 70 years were not
markedly different from those from the age of 50 years. The
reason for this is that increasing death and fracture hazards
with age compete in the determination of probability.
References
1. Hernlund E, Svedbom A, Ivergård M Compston J, Cooper C,
Stenmark J,McCloskey EV, Jönsson B, Kanis JA (2013) Osteoporosis
in the European Union: Medical Management, Epidemiology and
Economic Burden. A report prepared in collaboration with the
International Osteoporosis Foundation (IOF) and the European
Federation of Pharmaceutical Industry Associations (EFPIA). Arch
Osteoporos, in press
2. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey EV (2008)
FRAX™ and the assessment of fracture probability in men and
women from the UK. Osteoporos Int 19: 385–397.
3. Kanis JA, Odén A, McCloskey EV, Johansson H, Wahl D, Cyrus
Cooper C on behalf of the IOF Working Group on Epidemiology
and Quality of Life (2012) A systematic review of hip fracture
incidence and probability of fracture worldwide. Osteoporos Int 23:
2239–2256.
4. United Nations (2010) World Population prospects, the 2010
revision. Department of Economic and Social Affairs, UN (http://
esa.un.org/unpd/wpp/unpp/panel_indicators.htm) accessed 2nd No-
vember 2011
Fig. 7 Remaining lifetime probability of hip fracture (%) in men and
women from 21 countries in the EU from the age of 50 years [1]
Table 10 Criteria for allocating scores
Fig. 8 Remaining lifetime probability of hip fracture (%) in women in
the EU from the age of 50 years [1]
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1g Men and women at high fracture risk
Domain
Burden of disease—scorecard element
Background and aims
The advent of FRAX in 2008 [1] provided a clinical
tool for the calculation of fracture probability.
Probability-based assessment is increasingly being in-
corporated into clinical guidelines in Europe [2, 3] and
elsewhere. Unlike fracture incidence, the probability of
fracture at any given age depends upon the hazard of
death as well as the hazard of fracture over a defined
interval (e.g., 10 years or lifetime). A major advantage
of using fracture probability is that it standardises the
output from the multiple techniques and sites used for
assessment and also permits the presence or absence of
risk factors other than BMD to be incorporated as a
single metric. FRAX models are also calibrated to
country-specific epidemiology.
The ability to compute fracture probabilities in in-
dividuals permits an estimate of the prevalence of high risk
individuals within a given population where the population
demography and the distribution of FRAX-based probabil-
ities are known.
The aim of this score card element was to present the
burden of osteoporosis in men and women in the EU27
countries expressed as the proportion of the population that
has a 10 year probability of a major fracture (hip, spine,
forearm or humerus) above a given threshold.
Methods
There is no international standard for defining high risk
based on probabilities. In Europe, intervention thresholds
are commonly defined as the 10-year probability of a major
fracture that equals or exceeds that of a woman with a prior
fragility fracture [2, 3], termed the probability fracture
threshold. In North America threshold risks have been set at
probabilities of 10 and 20 % [4, 5] and these were used for
this assessment.
The majority of EU member states have a country-specific
FRAX model. Where unavailable, a surrogate model was
used. The distribution of FRAX probabilities in men and
women was simulated in 5-year age intervals for eachmember
state between the ages of 50 to 89 years [6] and applied to the
demography of each country for 2010 [7]. Burden of
disease was expressed as the number of men and women
with a probability of major fracture above a threshold of
10 or 20 %. For comparative purposes, the burden was
expressed as the proportion of the population aged 50–
89 years with probabilities above these thresholds.
Results
Approximately 12.9 million men and women in the EU27
have a 10-year fracture probability that is 20 % or more.
When a 10 % threshold is used the population at high risk
rises to 41.3 million, representing respectively 3 and 8 % of
the total EU population for 2010.
The proportion of the population aged 50 years or more
that in 2010 had a fracture probability of 20 % or more
varied among member EU states, ranging from 2 % in
Romania to 17 % in Sweden (Table 11). The proportion of
Table 11 Number of men and women (000) and proportion of the
population aged 50–89 years (%) with a 10-year probability of a major
fracture that exceeds 10 %, 20 % or the fracture threshold for women
Country Number of men and
women (000)
Proportion of population
aged 50–89 years (%)
>20 % >10 % >Fracture
threshold
>20 % >10 % >Fracture
threshold
Austria 407 1,101 325 14 37 11
Belgium 355 1,058 460 9 27 12
Bulgaria 51 308 330 2 11 12
Cyprus 20 68 36 6 22 12
Czech 293 926 431 8 25 11
Denmark 377 937 214 19 48 11
Estonia 24 92 60 5 19 13
Finland 109 402 222 5 20 11
France 1,667 4,638 2,717 8 21 12
Germany 2,434 7,840 3,773 7 24 12
Greece 333 1,110 524 8 27 13
Hungary 238 842 393 7 23 11
Ireland 110 339 141 9 28 11
Italy 2,093 6,592 2,864 9 28 12
Latvia 39 155 102 5 19 13
Lithuania 53 209 141 5 19 13
Luxembourg 13 39 18 8 25 12
Malta 10 35 18 7 23 12
Netherlands 221 881 681 4 15 12
Poland 375 1,567 1,540 3 12 12
Portugal 200 656 479 5 17 12
Romania 127 761 834 2 10 12
Slovakia 139 527 197 8 31 11
Slovenia 49 169 78 6 23 10
Spain 664 2,284 1,947 4 15 12
Sweden 567 1,437 398 17 42 12
UK 1,947 6,310 2,416 9 30 11
EU27 12,915 41,283 21,339
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the population aged 50 years or more that had a fracture
probability of 10 % or more ranged from 12 % in Romania
to 42 % in Sweden (Table 11). Figure 9 shows the rank
order of population burden.
For completion, the table also shows the number of men
and women that lie above a fracture threshold commonly used
in assessment guidelines. This is considered later in
relationship to the uptake of treatments in the EU27 (Chapter
4c).
Score criteria
Countries were ranked by tertiles of prevalence of the
population aged 50–89 years above a 10 % probability
threshold of a major osteoporotic fracture as given in Table
12.
Score allocation
The proportion of the population (%) aged 50–89 years
with a 10-year probability of a major fracture that is
10 % or more by member state is shown by category
and rank in Fig. 10.
Comment
The majority of EU member states have a country-specific
FRAX model. For those countries where a country-specific
FRAX model was unavailable, a surrogate model was used,
based on the estimate that the epidemiology of hip fracture
was similar. For Bulgaria, the Romanian model was used;
for Cyprus, the Maltese model was used; for Estonia and
Latvia, the Lithuanian model was used; for Luxembourg,
the Belgian model was used; and for Slovenia, the
Hungarian model was used.
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1h Population projections
Domain
Burden of disease—background information
Background and aims
Secular changes in life expectancy and birth rate are likely
to increase the number of elderly individuals in the EU
member states and thereby increase the need for resource
allocation for diseases associated with ageing. The
incidence of fragility fractures increases markedly with
age, particularly in women. The aim of this background
element is to estimate the increase in number of women
aged 50 years or more in the EU member states.
Methods
The age and sex distribution of the EU member states was
obtained from the UN for 2010 and 2025 using the medium
variant [1].
Results
The population of women over 50 years is expected to
increase by 22 % and in men by 17 % in the EU
between 2010 and 2025. The number of men and
women aged 50 years or more will increase in all
countries except Bulgaria, Hungary and Latvia (Table
13). In the remaining countries, the increment in the
population varies widely.
With some exceptions, the percentage increase in number
of men and women aged 75 or more years is greater than
that of the population aged 50–74 years. The exceptions
include Belgium (women), Bulgaria (men), Greece (men),
Lithuania (men), Luxembourg (women), Romania (men)
and Spain (men and women).
For women over the age of 75 years, the change in
the population ranged from less than 10 % in Latvia
(7 %) and Lithuania (9 %) to more than 40 % in
Cyprus, Denmark, Finland, Ireland, Malta and the
Netherlands (Fig. 11).
Table 13 Projected percentage change in the male and female
population between 2010 and 2025 according to category of age [1]
Country Men aged Women aged
50–74 years 75+years 50–74 years 75+years
Austria 25 57 22 26
Belgium 18 27 17 13
Bulgaria −1 −1 −3 11
Cyprus 36 57 31 63
Czech Republic 9 57 4 37
Denmark 10 70 10 45
Estonia 6 21 0 14
Finland 2 81 1 41
France 17 40 17 22
Germany 13 52 10 23
Greece 23 18 17 18
Hungary 6 19 −1 18
Ireland 37 73 38 53
Italy 25 35 18 21
Latvia 8 13 −2 7
Lithuania 12 3 6 9
Luxembourg 36 64 43 25
Malta 6 100 5 50
Netherlands 19 75 19 41
Poland 8 24 7 21
Portugal 22 31 17 25
Romania 14 6 10 19
Slovakia 22 38 16 32
Slovenia 18 60 15 25
Spain 42 33 35 22
Sweden 10 61 9 35
UK 17 46 17 29
Fig. 11 Projected increase by country in the female population aged
75 years or more (%) between 2010 and 2025 [1]
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The increase in the male population aged over
75 years was generally more marked than in women.
In men, the EU population aged 75 years or more is
expected to increase by 33 %. In those countries with
large expected changes in the proportion of the
population aged 75 years or more, the increment is
larger in men than in women (Fig. 12) since life
expectancy, lower in men, is improving more rapidly in
men than in women with time.
Score criteria
None—not a score card element
Comment
UN population projections over 15 years are relatively
robust in that all men and women in 2025 aged 50 years or
more had already attained adulthood in 2010. The pro-
jections expressed in relative change for countries with very
small populations are uncertain (e.g. Malta, Cyprus) since
population numbers are given by the UN rounded to the
nearest 1000.
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1i Fracture projections
Domain
Burden of disease—scorecard element
Background and aims
As noted, the number of men and women aged 50 years or
more is set to increasewith time in the EU. The increasewill be
particularly marked in the elderly population. Since age is an
important risk factor for fractures and the elderly population is
projected to increase in the majority of member countries, the
burden of fractures is also likely to increase.
Fig. 12 The relation between the percentage increase in the male and
female population aged 75 years or more in EU member states. The
diagonal shows the line of identity
Table 14 Number of fractures in men and women in 2010 and
number expected in 2025, and the percentage increase [2]
Country Number
of
fractures
2010
Number
of
fractures
2025
Δ
fractures
2010–
2025
(number)
Δ
fractures
2010–
2025 (%)
Share
of
EU27
increase
Austria 86,031 115,686 29,655 34 3
Belgium 79,201 98,525 19,324 24 2
Bulgaria 38,184 39,612 1,429 4 0
Cyprus 5,022 7,536 2,514 50 0
Czech
Republic
75,359 97,829 22,470 30 2
Denmark 66,066 86,094 20,028 30 2
Estonia 8,678 10,208 1,530 18 0
Finland 36,292 48,939 12,647 35 1
France 378,082 493,031 114,949 30 12
Germany 732,137 936,461 204,324 28 21
Greece 84,256 105,284 21,028 25 2
Hungary 90,011 101,544 11,533 13 1
Ireland 17,947 27,372 9,425 53 1
Italy 466,475 599,034 132,559 28 13
Latvia 14,284 16,204 1,920 13 0
Lithuania 15,084 17,484 2,400 16 0
Luxembourg 2,684 4,015 1,331 50 0
Malta 2,618 3,744 1,125 43 0
Netherlands 76,691 107,671 30,980 40 3
Poland 167,033 208,591 41,558 25 4
Portugal 51,329 68,448 17,119 33 2
Romania 94,240 110,099 15,858 17 2
Slovakia 38,363 49,508 11,145 29 1
Slovenia 15,471 21,795 6,323 41 1
Spain 203,794 285,453 81,659 40 8
Sweden 106,857 135,029 28,172 26 3
UK 535,724 681,956 146,231 27 15
EU27 3,487,914 4,477,152 989,238 28 100
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The aim of this scorecard element was to estimate the
increase in the annual number of fragility fractures from
2010 to 2025.
Methods
The incidence of hip fracture was determined from a
systematic literature review [1, 2]. For other fractures, it was
assumed that the age- and sex-specific incidence in relation
to hip fracture followed that documented for Sweden [3]
and other non-EU countries [4]. Outcomes included the
three most common sites of osteoporotic fracture (hip, spine
and forearm) as well as other fractures considered to be
associated with osteoporosis (i.e. pelvis, rib, humerus, tibia,
fibula, clavicle, scapula, sternum, and lower femur) [3]. For
vertebral fractures, only those coming to clinical attention
were included.
Fracture numbers were calculated from age- and sex-
specific incidence and population sizes in 5-year age intervals
for 2010 and 2025 [5]. It was assumed that the incidence of
osteoporotic fractures did not change over time.
Results
The annual number of osteoporotic fractures in the EU27 will
increase by 0.99 million from 3.49 million in 2010 to 4.48
million in 2025 (Table 14). The increase in the annual number
of fractures is found in all countries (Fig. 13), ranging from a
53% increase in Ireland to a modest 4% increase in Bulgaria.
In 2025, Germany is expected to have the largest number of
fractures with almost 940,000 fractures, followed by the UK
with 680,000.
Score criteria
Countries were ranked by the percentage increase in the
annual number of fractures in men and women between
2010 and 2025 as shown in Table 15.
Score allocation
The percentage increase in the annual number of fractures in
men and women between 2010 and 2025 is shown by
category and rank in Fig. 13.
Comment
The analysis assumes that the age- and sex-specific
incidence of fractures did not change over the 15-year time
interval. Secular trends in fracture risk are ill-documented
with the exception of hip fracture [6] where limited
information is available. In general, age- and sex-adjusted
hip fracture incidence increased until the mid or end of the
20th century, with a subsequent plateau or even a small
decrease [6]. In Europe, this tendency is best documented
for Sweden, Finland, Spain, Germany, Netherlands and
Hungary.
Countries with substantial increases in the number of
fractures need to take this into account for future healthcare
planning.
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Chapter 2 Policy framework
2a Quality of existing information
Domain
Policy framework—scorecard element
Background and aims
Fracture incidence is poorly documented in the EU [1]. The
fracture that has been best evaluated is hip fracture.Hip fractures
account for the majority of health care expenditure, mortality
and morbidity and can be used as a proxy for osteoporosis. The
EU comprises countries with some of the highest hip fracture
rates worldwide [2], but documentation of the size of the
problem and the quality of data vary between countries.
Documentation of the burden of disease is an essential
prerequisite to determine the resources that should be
allocated to the diagnosis and treatment of the disorder. It
also provides information concerning the priority a disease
should be awarded by healthcare policy makers. A fracture
registry is a centralised database collecting the number of
individual fractures per person, per year within a population
and is used for research and resource allocation. The data
collected can also be used to identify high-risk patients in
need of further prevention programs. The main objective of
this scorecard element is to provide an integrated estimate
of the quality of current documentation on the burden of
osteoporosis fractures in the countries of the European
Union.
Methods
Published information on hip fracture incidence was obtained
by systematic review, in some cases through contact with
Ministries of Health [2]. Available studies in each country
were reviewed for quality and representativeness of the
country. Epidemiology of other fractures was obtained by
systematic review [1].
Data on national or regional fracture registers [3] were
updated by an IOF questionnaire to the EU Osteoporosis
Consultation Panel.
The quality of the available information was scored,
with the presence of an established national fracture
register as the highest grade. In the absence of a
fracture register, an intermediate score was dependent
on the presence of good quality national hip fracture
rates.
Results
High quality national data on hip fracture rates were identified
in 15 member states (Table 16). Fair to poor quality national
estimateswere found for Lithuania and Slovenia. No datawere
available for four countries (Bulgaria, Cyprus, Latvia, and
Luxembourg). In the remaining six countries, regional
estimates of variable quality were identified. Most index years
included data from 2000 onwards.
Data on the incidence of clinical vertebral fractures are
lacking in most of the countries in the EU, the exceptions
being regional data for Sweden and the UK. In the UK, the
incidence of clinically identified fractures has been studied
within the General Practice Research Database (GPRD).
The incidence is, however, very low and it is likely that the
majority of fractures were not coded.
Information on forearm fracture is also scarce. Forearm
fractures are treated in hospital outpatient departments. There
are reports from EU27 countries on the incidence of forearm
fractures that lead to hospitalisation, e.g. fromFrance and Italy,
but these are of limited value. There are also studies published
from Slovenia and Italy which present incidence of forearm
fractures treated both in inpatient and outpatient care.
However, the Slovenian study only reports fractures occurring
in women, and the Italian study lacks age stratification of data
within the elderly population. Credible data are only available
for Hungary, the UK and Sweden [1].
National fracture registries were in place in 12 of the EU
countries (Table 16). Themajority of these acquire information
on all or several fracture outcomes (Austria, Denmark,
Finland, Germany, Hungary, Ireland, Latvia, Netherlands,
Portugal and Slovakia) and the remainder registered hip
fracture alone (Belgium, Ireland, Sweden and UK). In several
additional countries, local registers are available.
Score criteria
The presence of an established national fracture register was
allocated the highest grade. In the absence of a fracture
register, an intermediate score was given with the
availability of good quality national hip fracture rates.
Criteria for allocating scores are given in Table 17.
Score allocation
Countries, ranked and categorised by score, are shown in
Fig. 14.
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Comments
The quality of this information is limited. Firstly, it is based
on responses to a questionnaire to national societies and not
to government agencies. Secondly, centralised data are not
necessarily equivalent to a national registry.
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2b National health priority
Domain
Policy framework—scorecard element
Background and aims
Data from the Global Burden of Disease 2010 Study
indicate that musculoskeletal disorders are the second
greatest cause of disability as measured by years lived with
Table 17 Criteria for allocating scores
Fig. 14 Quality of information available on the epidemiology of hip
fractures in the EU [IOF audit]
Table 16 Characteristics of information available on fracture rates in
the European Union
Incidence of hip
fracture
Established National
Fracture Registries
Score
Qualitya Sampleb Present Datac
Austria G N Nod 3
Belgium G N Yes Hip 3
Bulgaria No 0
Cyprus No 0
Czech Republic G N No 2
Denmark G N Yes Hip+ 3
Estonia P R No 1
Finland G N Yes Hip+ 3
France G N Nod 2
Germany G N Yes Hip+ 3
Greece P/F/G R No 1
Hungary G N Yes Hip+ 3
Ireland G N Yes Hip 3
Italy G N Nod Hip+ 2
Latvia R Yes Hip+ 3
Lithuania F R No 1
Luxembourg No 0
Malta G N No 2
Netherlands G N Yes Hip+ 3
Poland F R No 1
Portugal G N Yes Hip+ 3
Romania G N No 2
Slovakia G N Yes Hip+ 3
Slovenia F N No 2
Spain F/G R Nod Hip+ 1
Sweden G R Yes Hip 3
UK G R Yes Hip 3
Responses derived from questionnaire to National Societies
a Quality: G good; F fair; P poor [2]
b Catchment: N national; R regional
cHip Registration of hip fracture only. Hip+ Registration of hip and
other fracture outcomes
d Regional registers available
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disability (YLD), worldwide and across most regions of the
world [1]. In terms of both death and disability, musculo-
skeletal diseases are the non-communicable diseases that
have the fourth greatest impact on the health of the world
population (6.8 %). They closely follow cardiovascular and
circulatory diseases (11.8 %), tumours (7.7 %), and
mental/behavioural disorders (7.4 %) [2]. Disability due to
musculoskeletal disorders has increased by 45 % from 1990
to 2010 compared to a 33 % average across all other disease
areas. These data suggest that musculoskeletal disease
merits a high priority in health care policy. Osteoporotic
fractures in Europe accounted for more disability-
adjusted life years lost (2,006,000 DALYs) than
rheumatoid arthritis (1,048,000) but less than that for
osteoarthritis (3,088,000) representing 33 % of the
DALYs of these disorders [3].
When a disease becomes a National Health Priority
(NHP), it is usually mandated by a government
body/ministry of health or another official institution.
Osteoporosis may be a designated NHP on its own, or it
may be included as part of a musculoskeletal diseases NHP.
The development of a national action plan, clear objectives
Table 18 Countries in which
osteoporosis or musculoskeletal
diseases were officially docu-
mented as a NHP, its scope and
action plans
Responses derived from ques-
tionnaire to National Societies
aN, E, F Nutrition, Exercise,
Falls prevention; P profession-
al education; FLS Fracture
liaison services
NHP and date Government
support
Scopea Action plan Score
Austria No – 1
Belgium No – 1
Bulgaria Yes 2006 Yes N, FLS Yes 3
Cyprus No 1
Czech Republic No 1
Denmark No 1
Estonia No 1
Finland Yes Yes N, E, F No 2
France Yes 2004 Yes N, E, F No 2
Germany No 1
Greece No 1
Hungary No – 1
Ireland No 1
Italy Yes 2005 Yes N, F Uncertain 2
Latvia No 1
Lithuania No 1
Luxembourg Yes Yes N, E, F Yes 3
Malta No 1
Netherlands No 1
Poland No 1
Portugal Yes 2004 Yes P Rarely implemented 2
Romania Yes Yes Case finding Yes 3
Slovakia No 1
Slovenia No 1
Spain No 1
Sweden Yes 2012 Yes Not yet defined No 2
UK Yes 2009 Yes NE, FLS Indirect 3
Table 19 Criteria for allocating scores
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and support for education and awareness programs also
often result from a NHP mandate. The aim of this scorecard
element was to determine the extent to which member states
have recognised this need.
Methods
Information on NHP [4] was updated by an IOF
questionnaire to the EU Osteoporosis Consultation Panel
undertaken in December 2012.
Respondents were asked whether osteoporosis or
musculoskeletal diseases were officially documented as
a NHP in each member state and to provide the
documentary evidence. Further questions related to
action plans linked to the NHP and their implementa-
tion.
Results
The majority of member states (18/27) do not recognise
osteoporosis or musculoskeletal diseases as a NHP
(Table 18). Of those member states that have developed
a NHP, the focus has been on nutrition (six countries),
falls prevention (four countries), exercise (four coun-
tries), and the institution of fracture liaison services (two
countries). Action plans have been implemented in
Bulgaria, Luxembourg and Romania. There is scant
evidence for the implementation of action plans in
Finland, France, Italy and Portugal. In Sweden, osteo-
porosis has only recently become a NFP (2012). In the
UK, implementation is indirect via the establishment of
quality indicators in the audit of primary care practice
(see Chapter 3h).
Score criteria
The presence of government-backed NHP with an
implemented action plan was allocated the highest grade.
In the absence of an action plan, an intermediate score was
given. Criteria for allocating scores are given in Table 19.
Score allocation
Countries, ranked and categorised by score, are shown inFig. 15.
Comment
Unless osteoporosis prevention and treatment become a
priority for governments and health care providers, the
growing number of osteoporotic fractures will have a
serious impact on society—not just in terms of people’s
quality of life, but also because of increased costs incurred
for acute healthcare, rehabilitation and nursing care.
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2c Who manages osteoporosis?
Domain
Policy framework—scorecard element
Background and aims
In 2010, it is estimated that 22 million women and 5.5
million men in the EU had osteoporosis using the diagnostic
criterion of the WHO [1]. In 2010, the number of new
osteoporosis-related fractures in the EU was estimated at 3.5
million, comprising approximately 610,000 hip fractures,
520,000 vertebral fractures, 560,000 forearm fractures and
1,800,000 other fractures (i.e. pelvis, rib, humerus, tibia,
fibula, clavicle, scapula, sternum, and other femoral
fractures). Osteoporosis is a common disease and effective
treatments are widely available. As such, in most health care
systems the vast majority of patients with osteoporosis is
preferably managed at the primary health care level by
general practitioners with specialist referral reserved for
difficult cases, for example men and individuals in whom a
secondary cause of osteoporosis is suspected.
The aim of this element was to determine whether the
care of osteoporosis was primarily devolved to primary care
physicians (GPs, family doctors). If not, then the lead
specialty was asked for. The training of specialists is
considered in Chapter 2d.
Methods
Data were acquired by an IOF questionnaire to the EU
Osteoporosis Consultation Panel undertaken in December
2012. Respondents were asked whether osteoporosis was
primarily devolved to primary care physicians (GPs, family
doctors). If not, the single specialty that looked after most
cases of osteoporosis was asked. In the case where there
Table 20 Care pathway for patients with osteoporosis by country
Primarily
devolved to
primary care
Lead specialty Score
Austria yes 3
Belgium yes 3
Bulgaria no Rheumatology,
endocrinology
1
Cyprus yes 3
Czech Republic no Clinical osteology,
endocrinology
1
Denmark no Rheumatology,
endocrinology
1
Estonia yes 3
Finland yes 3
France yes 3
Germany no Orthopaedics,
clinical
osteology
Greece no Orthopaedics 2
Hungary no Rheumatology 2
Ireland no Rheumatology,
endocrinology,
geriatrics
1
Italy no Rheumatology,
endocrinology
1
Latvia yes 3
Lithuania yes 3
Luxemburg yes 3
Malta no Rheumatology,
gynaecology,
endocrinology,
geriatrics
1
Netherlands yes 3
Poland no Rheumatology,
orthopaedics,
rehabilitation
medicine, internal
medicine
1
Portugal yes 3
Romania no Rheumatology,
endocrinology
1
Slovakia no Rheumatology,
orthopaedics,
endocrinology
1
Slovenia yes 3
Spain yes 3
Sweden yes Rheumatology,
orthopaedics,
endocrinology,
internal medicine,
geriatrics
3
UK yes 3
Responses derived from questionnaire to National Societies
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was near equality between two or more specialties, they
were each recorded.
Results
Primary care was the principal provider of the medical care
of osteoporosis in 15 of the 27 EU member states (Table
20). In the remainder, the principal care was provided by
hospital specialists. In Greece and Hungary, a single
hospital specialty was the dominant provider (orthopaedics
and rheumatology, respectively). In the remaining countries,
the care of osteoporosis was split between disciplines. The
number of disciplines was usually two (Bulgaria, Czech
Republic, Denmark, Germany, Italy and Romania) but was
three in the case of Ireland and Slovakia, and four or more
for Malta, Poland and Sweden. The specialties involved
comprised rheumatology (noted 10 times), endocrinology
(9), orthopaedics (5), geriatrics (3), clinical osteology (2),
internal medicine (2) gynaecology (1) and rehabilitation
medicine (1). The panel were concerned by the multiplicity
of specialists that had a primary role in the care pathway of
patients in some countries and viewed this as an
impediment to consistent care.
Score criteria
Where the care of osteoporosis was primarily devolved
to primary care physicians (GPs, family doctors), this
was allocated the highest grade. If not, then an
intermediate score was given where osteoporosis is
mainly managed by a single specialty, as given in
Table 21.
Score allocation
Countries, ranked and categorised by score, are shown in
Fig. 16.
Comment
Care management pathways are not necessarily divided by
primary care and specialty care. The panel supports the
view that long-term management should preferably be
undertaken by GPs, contingent on adequate training, but
there is a specialist role in initial evaluation, particularly in
the context of fracture liaison services (see Chapter 3g). In
Table 21 Criteria for allocating scores
Fig. 16 Patterns of principal
care of patients with
osteoporosis [IOF audit]. *See
comment below
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Germany, there is the opportunity for specialists in many
disciplines to be specially trained and accredited in the
primary care of patients with osteoporosis. These consid-
erations should temper the interpretation of the scores
allocated.
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2d Is osteoporosis a component of specialty training?
Domain
Policy framework—scorecard element
Background and aims
The large number of men and women who suffer the
consequences of osteoporosis raises the question of whether
there is adequate training of medical practitioners in this
specialty and, indeed, which specialty takes a leadership
role.
The aim of this background element was to determine
whether osteoporosis and metabolic bone disease are a
recognised specialty or recognised component of specialty
training.
Methods
Data were acquired by an IOF questionnaire to the EU
Osteoporosis Consultation Panel undertaken in Decem-
ber 2012. Information requested included whether
osteoporosis or metabolic bone disease is a recognised
medical specialty in each country. Also asked was
whether osteoporosis or metabolic bone disease is a
recognised component of specialty medical training and,
finally, which specialists took lead roles in the care of
osteoporosis.
The available information was scored, with the presence
of an established specialty as the highest grade. In the
absence of osteoporosis or metabolic bone disease being a
recognised medical specialty, an intermediate score was
dependent on the disorder being a recognised component of
specialty medical training.
Results
Osteoporosis and metabolic bone disease is a recognised
specialty in only four of the EU member states (Czech
Republic, Denmark, Estonia and Lithuania). In some
countries, there are specialists that deal exclusively with
metabolic bone diseases (e.g. the UK) most usually in
an academic setting. The more usual finding is that the
specialty care of osteoporosis is via another specialty
(Table 22). The specialties involved include endocrinol-
ogy, geriatrics, gynaecology, internal medicine, ortho-
paedic surgery, rehabilitation medicine and rheumatol-
ogy. In the majority of countries, osteoporosis or
metabolic bone disease is a recognised component of
specialty medical training but there is no information on
the extent to which this is taken advantage of. In
Germany, a postgraduate training in clinical osteology is
available to specialists from different disciplines to
become certified. In two countries (Ireland and Poland)
osteoporosis was neither an accepted medical specialty
nor a component of specialty medical training. In the
UK, experience in metabolic bone disease may form a
component of specialist training but is not mandatory.
With the exception of Slovakia, the lead specialties are
multiple. In some countries, all seven specialties took what
were considered lead roles in the management of osteopo-
rosis. This clearly indicates that there is no dominant
specialty that looks after osteoporosis in any one country
and a great diversity between countries. The specialty
representation is illustrated in Fig. 17.
Score criteria
The highest score was allocated to a country if
osteoporosis or metabolic bone disease was an
established specialty. In the absence of osteoporosis or
metabolic bone disease being a recognised medical
specialty, an intermediate score was dependent on the
disorder being recognised component of specialty
medical training (Table 23).
Score allocation
The score allocation and grade for each country is shown in
Fig. 18.
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Fig. 17 The specialty
representation in the EU
countries. Note that more than
one specialty per country can
be represented (see Table 22)
[IOF audit]
Table 22 Specialists caring for
osteoporosis (OP)
Responses derived from ques-
tionnaire to National Societies
aEndo endocrinology, Ger geriat-
rics,Gyn gynaecology, Int internal
medicine, Orth orthopaedic sur-
gery, Rehab rehabilitation medi-
cine, Rh rheumatology
OP recognised as
a specialty
Lead specialistsa OP recognised as a
component of
specialty training
Score
Austria No Rh, Orth, Gyn, Endo, Int Yes 2
Belgium No Rh, Gyn, Endo, Ger, Rehab, Int Yes 2
Bulgaria No Orth, Gyn, Int Yes 2
Cyprus No Rh, Orth, Gyn, Endo, Int Yes 2
Czech Republic Yes Rh, Orth, Gyn, Endo, Int Yes 3
Denmark Yes Ger Yes 3
Estonia Yes Orth, Endo, Rh Yes 3
Finland No Rh, Orth, Gyn, Endo, Ger, Rehab, Int Yes 2
France No Rh, Gyn, Endo, Ger Yes 2
Germany No Rh, Orth, Gyn, Endo, Ger, Rehab, Int Yes 2
Greece No Rh, Gyn, Endo Yes 2
Hungary No Rh, Orth, Gyn, Endo,Rehab, Int Yes 2
Ireland No Rh, Gyn, Endo, Ger, Rehab No 1
Italy No Rh, Endo, Ger, Rehab, Int Yes 2
Latvia No Rh, Endo, Int Yes 2
Lithuania Yes Rh, Orth, Endo, Ger, Rehab, Int Yes 3
Luxembourg No Rh, Orth, Gyn, Endo, Ger, Rehab, Int Yes 2
Malta No Rh Orth, Gyn, Endo,Rehab, Int Yes 2
Netherlands No Rh, Orth, Endo, Ger, Int Yes 2
Poland No Rh, Orth, Endo, No 1
Portugal No Rh, Orth, Gyn, Endo, Ger, Rehab Yes 2
Romania No Orth, Rehab Yes 2
Slovakia No Gyn Yes 2
Slovenia No Rh, Gyn, Endo,Rehab Yes 2
Spain No Rh, Orth, Gyn, Endo, Ger, Rehab, Int Yes 2
Sweden No Rh, Orth, Endo, Int Yes 2
UK No Rh, Orth, Endo, Ger, Gyn Yes 2
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Comment
There is a wide variation in the specialties which cater for
osteoporosis. Although it is possible that these specialties educate
their trainees adequately, the wide variation may be reflected in
inconsistent patient care, trainingof primary care physicians and a
suboptimal voice to “defend” the interests of osteoporosis.
2e National Societies
Domain
Policy framework—scorecard element
Background and aims
The role of national patient societies is to improve the care
of patients and increase awareness and prevention of
osteoporosis and related fractures among the general public.
In addition to their role in patient and public outreach, the
societies provide practical and unbiased information for
osteoporosis patients and their families through telephone
help lines, local self-help groups and information events,
media outreach, general educational activities and by
distributing information via brochures and their websites.
The patient societies often work closely with clinical and
research associations to disseminate information about new
treatments and patient guidelines. Finally, with their often
large and active membership base, societies play an
important role in advocacy by calling for access to timely
and affordable diagnosis and treatment. This is particularly
necessary for osteoporosis which, as a chronic ‘silent’
disease, is too often neglected by health authorities.
Methods
Data were acquired from the International Osteoporosis
Foundation on the patient-contact societies operating in the
European Union. Support societies fall into three categories:
those primarily involved with direct patient contact (e.g. a
Table 23 Criteria for allocating scores
Fig. 18 The score allocation and grade for specialist training in each
country [IOF]
Table 24 The number and type of osteoporosis societies in the EU
member states [IOF Audit]
Patient contact Patient orientated Scientific Score
Austria 1 1 3 3
Belgium 1 – 1 3
Bulgaria – 2 2 2
Cyprus – 1 1 2
Czech Republic – 1 2 2
Denmark – 1 1 2
Estonia – – 1 1
Finland – 1 1 2
France – 2 3 2
Germany 4 2 3 3
Greece – 1 3 2
Hungary – 1 1 2
Ireland 1 – – 3
Italy 1 4 4 3
Latvia 1 – 1 3
Lithuania – 1 2 2
Luxemburg – – 1 1
Malta – – 1 1
Netherlands – 1 1 2
Poland – 1 3 2
Portugal – 1 2 2
Romania – 1 3 2
Slovakia – – 2 1
Slovenia 1 – 1 3
Spain – 2 3 2
Sweden 1 1 2 3
UK 1 – 1 3
EU27 8/27 18/27 26/27
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help line), societies that are patient-orientated but without
patient contact and scientific societies that have no outreach
to patients. A high score was allocated to those countries
with a patient-contact/support society. In its absence, an
intermediate grade was allocated to patient-orientated
societies and the lowest score to countries with scientific
societies and no patient outreach.
Results
The individual societies are listed in the acknowledge-
ments. The distribution of type of society and number
by member state is shown in Table 24. Eight countries
had a patient-contact society. For patient-orientated
societies, there were 26 societies in 18 member states.
There were 49 scientific societies in 26 member states
(the exception was Ireland).
Score criteria
Support societies was categorised by patient contact (Table 25).
A high score was allocated to those countries with a patient-
contact society. In its absence, an intermediate grade was
allocated to patient-orientated societies and the lowest score to
countries with scientific societies and no patient outreach.
Score allocation
The score for each country by score and rank is shown in Fig. 19.
Comment
The score is based on the audit by the IOF of its affiliated
societies. As such, it necessarily did not consider societies that are
not members of the IOF Committee of National Societies. This
consideration should temper the interpretation of this element.
Table 25 Criteria for allocating scores
Fig. 19 Society support to os-
teoporosis by score [IOF audit]
144, Page 32 of 63 Arch Osteoporos (2013) 8:144
Chapter 3. Service provision
3a Treatments for osteoporosis
Domain
Service provision—scorecard element
Background and aims
A wide variety of approved drug treatments is available
for the management of osteoporosis. Potential limitations
of their use in member states relate to reimbursement
policies which may impair the delivery of health care.
The aim of this scorecard element was to review the
provision of medical intervention in each member state and,
in particular, to determine whether restricted reimbursement
was considered an obstacle to the accessibility and long-
term uptake of interventions.
Methods
Information on access to treatment [1] was updated by
an IOF questionnaire to the EU Osteoporosis Consul-
tation Panel undertaken in December 2012. Information
requested included the treatments that are currently
reimbursed, the level of reimbursement, the conditions
on which reimbursement are offered and whether
reimbursement policy interferes with what patients
could accept or physicians in each country would wish
to recommend to patients. We additionally asked
whether there are designated first-line treatments in
each country.
The following interventions were included: the
bisphosphonates (alendronate, ibandronate, risedronate
and zoledronic acid), raloxifene, denosumab, strontium
ranelate, parathyroid hormone derivatives (PTH and
teriparatide) and vitamin D analogues (alfacalcidol and
calcitriol). We excluded gonadal steroids (prescribed for
hypogonadal states rather than for osteoporosis) and
calcium/vitamin D products (most usually available
without prescription).
Costs for first- and second-line treatment per year
(weighted on price and market share in each country) were
taken from Hernlund [2].
The available information was scored on the basis of
full or partial reimbursement. In those countries with
restricted reimbursement, countries were identified where
reimbursement policy interfered with what patients could
accept or physicians would wish to recommend to
patients.
Results
Most interventions were reimbursed in most countries.
Full reimbursement was provided in only 7 of 26 EU
member states (Table 26). In the remaining countries,
the level of reimbursement ranged from 0 (Malta) to up
to 100 % for selected treatments (Luxembourg and
Spain). Restricted reimbursement was reported as a
significant obstacle to accessibility and long-term
uptake in several countries. Examples include
unaffordable cost to the patient (Spain), age restrictions
for some agents (Belgium, Italy, Poland), less reim-
bursement in the absence of a prior fracture (Estonia),
and reimbursement for some or all agents conditional
on a specialist referral (Czech Republic, Greece and
Hungary).
In several countries, reimbursement was conditional
on clinical criteria, which prevented health care pro-
fessionals from prescribing some or all agents to
individuals at high risk. Examples include reimburse-
ment criteria based on BMD alone (i.e. irrespective of
prior fractures in osteopenic cases) (Bulgaria, Lithuania,
Romania), patients at high risk identified by FRAX
(Belgium). In France, the intricacies of reimbursement
are considered as too complicated by GPs so that many
have lost interest in managing the disease. As might be
expected, impedimenta were less frequent in those
countries with full reimbursement (7/8) than in those
with incomplete reimbursement (10/19).
First-line drugs were mandated in 18 of 29 countries. The
majority comprised the oral bisphosphonates and, in
particular generic alendronate.
As expected, the average cost of intervention
(weighted on price and market share in each country)
varied markedly and ranged from € 160 (Belgium) to €
1269 (Demark). There was similar price inequality for
generic alendronate (Table 26).
In several countries, some registered treatments were
not reimbursed which are listed by treatment in Table
27.
Score criteria
The highest score was allocated for full reimbursement.
In those countries with restricted reimbursement, coun-
tries were identified where reimbursement policy inter-
fered with what patients could accept or physicians
would wish to recommend to patients. Categories are
shown in Table 28.
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Score allocation
Countries, ranked and categorised by score, are shown in
Fig. 20.
Comment
Note that full reimbursement does not necessarily denote
full access to treatment. For example, in Germany and the
UK, the availability of drugs other than generic alendronate
is restricted, sometimes severely so, by regional or local
budgetary policies.
Table 26 Levels of reimburse-
ment, reported barriers to care
from reimbursement policies
and costs of treatment [IOF
audit]
aDepending on income; nr not
recorded;
Reimbursed (%) Patient or
professional
impediment
First-line
drugs
identified
Average
cost (€/year)
Generic
alendronate
(€/year)
Austria 100 No Yes 257 174
Belgium 10–20 Yes Yes 160 123
Bulgaria 25 Yes No 179 80
Cyprus 100a No No 640 327
Czech Republic 50–90 No Yes 359 187
Denmark 50–90 No Yes 1269 126
Estonia 50–90 Yes No 232 171
Finland 40 No Yes 205 40
France 30–65 Yes Yes 412 209
Germany 100 No Yes 619 245
Greece Part Yes No 391 239
Hungary 70–90 Yes Yes 354 115
Ireland 100a No No 570 240
Italy 100 Yes No 619 294
Latvia 50 No nr 308 85
Lithuania 50–80 Yes Yes 409 146
Luxembourg 80–100 No No 336 109
Malta 0 No Yes 545 190
Netherlands 100 No Yes 226 4
Poland 30 Yes No 581 245
Portugal 69 No Yes 313 16
Romania 50 Yes Yes 173 53
Slovakia 90+ No Yes 401 16
Slovenia 100 No Yes 234 161
Spain 50–100 Yes Yes 478 201
Sweden 100 No Yes 667 27
UK 100 No Yes 226 13
Table 27 Registered treatments that are not reimbursed [2]
Treatment Countries where reimbursement is not offered
for osteoporosis
Risedronate Estonia, Malta
Alendronate Malta
Ibandronate Malta, Poland, Sweden
Zoledronic acid Estonia, Malta, Poland, Romania
Raloxifene Bulgaria, Latvia, Malta, Poland
Denosumab Estonia, France, Malta, Portugal, Romania
Strontium Ranelate Malta, Poland
Teriparatide and
PTH (1–84)
Bulgaria, Estonia, Luxembourg, Malta,
Netherlands, Poland, Romania
Alfacalcidol/calcitriol Belgium, Denmark, France, Ireland, Poland
Table 28 Criteria for allocating scores
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The large price range of generic alendronate (€4 to €294
per year) is remarkable as an index of inequality of
provision within the EU.
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3b Availability of DXA
Domain
Service provision—scorecard element
Background and aims
The assessment of bone mass forms a cornerstone for the
general management of osteoporosis being used for diagnosis,
risk prediction, selection of patients for treatment and
monitoring of patients on treatment. The appropriate sites
and technology are measurement at the lumbar spine and hip
with dual-energy X-ray absorptiometry (DXA). The capacity
to service these needs depends therefore on the availability of
equipment.
The aim of this score card element was to compare the
availability of DXA in the EU member states.
Methods
An estimate of the number of operational DXA machines
was determined from the combined sales information of the
three major providers (GE Lunar, Hologic and Norland)
provided in confidence to the IOF [1]. The metric for each
country was the number of DXA units/million of the
general population.
Fig. 20 Ranking and score for
access to medical intervention
[IOF audit]. *See comment
below [IOF audit]
Table 29 The number of central DXA units available in the EU27 per
million of the general population [1]
Country DXA
units/
million
Country DXA
units/
million
Country DXA
units/
million
Austria 28.7 Germany 21.1 Netherlands 10.7
Belgium 53 Greece 37.5 Poland 4.3
Bulgaria 1.2 Hungary 6.0 Portugal 26.9
Cyprus 23.9 Ireland 10.0 Romania 2.4
Czech
Republic
5.2 Italy 18.6 Slovakia 10.7
Denmark 14.6 Latvia 4.9 Slovenia 27.1
Estonia 8.9 Lithuania 3.4 Spain 8.4
Finland 16.8 Luxemburg 2.0 Sweden 10.0
France 29.1 Malta 9.7 UK 8.2
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Results
The number of DXA units expressed per million of the general
population varied markedly in the EU (Table 29). Belgium,
Greece and France were the most well provided for and
Bulgaria, Luxembourg and Romania the least. Previous
surveys have indicated a marked heterogeneity in the
availability of DXA in the EU [2–4] and the present survey,
based on manufacturer sales, confirms this finding (Fig. 21).
Score criteria
The score was based on the number of DXA units/million of
the general population categorised by tertiles given in Table 30.
Score allocation
Countries, ranked and categorised by score, are shown inFig. 21.
Comment
The requirement for assessing and monitoring the treatment
of osteoporosis to implement practice guidelines has been
estimated at approximately 11 DXA units per million of the
general population [2]. The survey indicated that about
50 % of countries in the EU had the recommended number
of DXA machines for their population. It is important to
note that the figures provided do not distinguish between
machines dedicated in part or in full to clinical research, and
those that lie idle or are underutilised because of lack of
funding. It is likely, therefore, that a majority of countries
are under-resourced in the context of their practice
guidelines.
The granularity of the data means that it is not
possible to determine the use of DXA equipment (for
research or service), the efficiency and quality of service
or the extent of inequity of geographic distribution of
DXA machines.
References
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Table 30 Criteria for allocating scores
Fig. 21 DXA units/million of
the general population in 2010
based on sales of DXA in the
EU supplied by manufacturers
[1]. The horizontal line denotes
a minimum service requirement
[2]
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3c Access to DXA
Domain
Service provision—Scorecard element
Background and aims
The assessment of osteoporosis does not solely depend on the
availability of bonemassmeasurements at the lumbar spine and
hip with dual-energy X-ray absorptiometry (DXA) (see chapter
3b). Access also depends upon the efficiency with which the
technology is used, the ease of patient access (e.g. travelling
time), regulatory constraints and barriers to reimbursement.
The aim of this background element was to compare the
access to DXA in the EU member states.
Methods
Data were acquired by means of an IOF questionnaire
sent to the EU Osteoporosis Consultation Panel
undertaken in December 2012. Respondents were asked
to update previous estimates for the cost, waiting time
and reimbursement for DXA. Where information was
lacking, data for waiting times and reimbursement were
taken from the 2008 IOF EU audit or the Eastern
European and Central Asian Audit [1, 2]. Respondents
were specifically invited to comment on whether the
Table 31 Cost and reimburse-
ment of DXA [IOF audit]
n.r. Data not recorded
aAverage of range
bData from [1]
Country Waiting time
(d)
Cost
(€)
Reimbursement Barriers to clinical practice
Austria 14 35 Yes For some indications and <65 years
Belgium 14 42.5a Partial Yes, in case of rather low-risk profile
Bulgaria 0 37.5a None Depends on income
Cyprus 20 70 Yes (depending on
income)
n.r.
Czech
Republic
40a 25 Yes For some indications
Denmarkb 30 35 Yes No
Estonia 14 17 Yes n.r.
Finland 1 105a Yes No
France 14 40 Yes (conditional) Dependent on clinical risk factors.
Algorithm is considered as too
complicated for most GPs
Germany 0 45 Yes Reimbursed only after fracture
Greeceb 11a 52 Yes No
Hungary 15a 30 Yes Reimbursed only for women
Ireland 140a b 100 Yes (conditional) Reimbursed if privately insured.
Otherwise, depending on income
Italy 83a 50a Yes (conditional) For some indications
Latvia 10a 23.5a Yes No
Lithuania 6a 21.5a No No
Luxembourg 30 35a Yes No
Malta 105a 184b Yes For some indications
Netherlands 14a 105 Yes No
Poland 1 20a Yes (conditional) Reimbursement only if seen by specialists
Portugal 8 50a Yes No
Romania 7 22.5a Yes Yes
Slovakia 18a 30 Yes No
Slovenia 11a 40 Yes (conditional) Reimbursement only for secondary
osteoporosis
Spain 105a 41a Yes No
Sweden 60 90 Yes No
UK 11a 99 Yes Yes
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reimbursement policy (or lack of reimbursement) provided
barriers to the physician’s assessment of patients.
Results
The average waiting time for DXA ranged from 0 (Bulgaria
and Germany) to 140 days (Ireland) (Table 31 and Fig. 22).
There was no clear relation between waiting times and the
availability of DXA (see chapter 3b). For example, the
average waiting time in Italy was reported to be 83 days,
though the number of DXA machines is high (18.6
machines/million of the general population). This disparity
arises because many of DXA units lie in research centres or
the private sector and are unavailable to the majority of the
population. Conversely, there is no waiting time in Bulgaria
where the provision of DXA is low (1.2 DXA
units/million). The latter observation reflects the fact that
the few machines available are only used to service
specialised departments and that BMD assessments are
unavailable to the vast majority of the population at risk.
Thus, a disparity between the availability of equipment and
waiting time identifies a high heterogeneity in the use of
BMD to assess osteoporosis. A further consideration is the
uneven geographical location of equipment, which is
known to be problematic in Italy, Spain and the UK.
Reimbursement for DXA scans varied widely between
member states both in terms of the criteria required and
level of reimbursement awarded, and a majority of countries
provided full reimbursement (Table 31). In others, reim-
bursement or partial reimbursement was limited and usually
dependent on physician referral for approved indications,
sometimes restricted to criteria that did not satisfy the
requirements of good clinical practice. An example is seen
in Bulgaria (and incidentally in Switzerland) where
reimbursement is only offered if the BMD test turns out to
be positive (i.e. shows osteoporosis). Other examples of
restricted access included reimbursement only for limited
indications (Austria, Czech Republic, Malta and Slovenia),
only if seen by a specialist (Poland), only for women
(Hungary) and only after fracture (Germany).
The cost of DXA also varied widely (Table 31) and bore
little relation to the wealth of the nation or to the availability of
DXA machines.
Score criteria
The highest score was allocated for unconditional reimburse-
ment. In those countries with restricted reimbursement,
countries were identified where reimbursement interfered
with what patients could accept or physicians would wish to
recommend to patients. Categories are shown in Table 32.
Score allocation
Countries, ranked and categorised by score, are shown in
Fig. 23.
Fig. 22 Reported average
waiting time for a DXA
assessment by EU country [IOF
audit]
Table 32 Criteria for allocating scores
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Comment
There is a remarkable disparity between the availability of
equipment and waiting time, which reflects a high heteroge-
neity in the use of BMD to assess osteoporosis. Unimpeded
access to DXA is confined to a minority of member states.
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3d Access to risk assessment algorithms
Domain
Service provision—scorecard element
Background and aims
The effective targeting of treatment to those at highest risk of
fracture requires an assessment of fracture risk. Historically,
the targeting of treatment became feasible with the advent of
bonemineral density measurements. The causation of fragility
fractures is, however, heterogeneous and many additional
factors have been identified that contribute to fracture risk. In
turn, this has led to the development of risk algorithms that can
enhance the assessment of fracture risk to better target
interventions, particularly in primary care.
There are several assessment tools available in Europe
[1–5]. The most widely used is FRAX®. FRAX is a
computer-based algorithm (http://www.shef.ac.uk/FRAX)
that calculates the 10-year probability of a major fracture
(hip, clinical spine, humerus or wrist fracture) and the 10-
year probability of hip fracture. Fracture risk is calculated
from age, body mass index and well validated dichotomized
risk factors. Femoral neck bone mineral density (BMD) can
be optionally input to enhance fracture risk prediction.
Fracture probability differs markedly in different regions of
the world so that FRAX is calibrated to those countries
where the epidemiology of fracture and death is known
(currently 50 countries). In addition to the web site,
FRAX has been incorporated into the software of
densitometers and is available as an application for the
iPhone/iPad.
The aim of this scorecard element was to document the
availability of country-specific risk assessment models
(their uptake is considered separately in Chapter 4b). The
score was based on the availability of risk assessment
models and specific guidance for their use.
Methods
The availability of country-specific FRAX models was
provided at the FRAX web site. The availability of other
risk engines was determined from an IOF questionnaire
to the EU Osteoporosis Consultation Panel undertaken in
December 2012 together with a review of country-
specific assessment guidelines. The metrics sought were
the availability of country-specific risk models and
whether national guidance was provided on how results
from these assessments should be used in clinical
practice.
Fig. 23 Categorisation of
access to DXA by score in the
EU27 [IOF audit]
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Results
Risk assessment models were available in 21 of the member
states (Table 33). The majority were based on FRAX. In
Germany, probability-based fracture risk assessment com-
prises a component of national guidelines, but is not FRAX-
based [1]. Alternative assessment algorithms are also available
in the Netherlands [3]. In the UK both FRAX and QFracture
has been approved [6]. No models are available for Bulgaria,
Cyprus, Estonia, Latvia, Luxembourg and Slovenia due to the
lack of appropriate epidemiology of fracture on which these
could be based. In countrieswhere amodel is available, a small
majority (12/21) provide guidance on its application to clinical
practice.
European guidance that can be applied to member states
has been recently published for postmenopausal and
glucocorticoid-induced osteoporosis [7, 8].
Score allocation
The score was based availability of country-specific risk models
andwhether national guidancewas provided on how results from
these assessments should be used in clinical practice as given in
Table 34.
The score assigned to each country is shown in Fig. 24.
Comment
Risk assessment models for fractures based on FRAX
were available in 21 out of 27 countries. In some
countries (UK, Germany and the Netherlands) other
models are also available. However, guidance on the use
of risk assessment was available in only 12 out of 27
countries.
Table 33 Provision of risk assessment models in the EU and guidance
on their application to clinical practice
FRAX model
available
Other
models
Guidance Comments
Austria ✓ – ✓
Belgium ✓ – ✓
Bulgaria – – –
Cyprusa – – –
Czech
Republic
✓ – No
Denmark ✓ – No
Estonia – – –
Finland ✓ – ✓
France ✓ – ✓
Germany ✓ Yes ✓ DVO model [1]
Greece ✓b – ✓
Hungary ✓ – ✓
Ireland ✓b – –c
Italy ✓ – –c
Latvia – – –c
Lithuania ✓b – No
Luxemburg – – –c
Malta ✓ – No
Netherlands ✓ Yes ✓ CBO [3]
Poland ✓ – ✓
Portugal ✓b – ✓
Romania ✓ – –c
Slovakia ✓ – Noa
Slovenia – – No
Spain ✓ – No
Sweden ✓ – ✓
UKd ✓ Yes ✓ QFracture [2]
Europe – – ✓
a Uses Greek FRAX tool as a surrogate model
b Available from June 2012 and September 2012 (Portugal);
cNoted in guidelines but without guidance; c to be implemented.
d Guidance not provided by NICE
Fig. 24 The score assigned to each country on the basis of its
provision of fracture risk assessment algorithms. The star denotes that
guidance given by the National Osteoporosis Guideline Group scores 3
but the score based on NICE is less
Table 34 Criteria for allocating scores
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3e Quality of guidelines for assessment and treatment
Domain
Service provision—scorecard element
Background and aims
The aim of guidelines is to provide an information platform
for the assessment and treatment of osteoporosis so that
appropriate treatment is directed to individuals at high
fracture risk. Their scope most commonly includes
postmenopausal osteoporosis, glucocorticoid-induced oste-
oporosis and osteoporosis in men. Less commonly,
guidelines are available for the assessment of falls risk
and its treatment. Ideally, guidelines should be based on
systematic literature reviews and any recommendations
supported by an adequate level of evidence.
The aim of this scorecard element was to determine the
scope and quality of guidelines available in the EU27
countries.
Table 35 Availability and scope of guidelines for the assessment and
treatment of osteoporosis in the EU [IOF audit]
Developed
(year)
Scopea AGREE
criteria
Score
Austria 2010 PMW, men, GIOP 5 8
Belgium 2005–11 PMW, men, GIOP 4 7
Bulgaria 2007 PMW, men, GIOP 6 9
Cyprus na – 0 0
Czech Republic 2003–10 PMW, GIOP 4 6
Denmark 2009 PMW 4 5
Estonia 2012 PMW, men, GIOP 5 8
Finland 2013 PMW, men, GIOP 7 10
France 2012 PMW, men, GIOP 5 6
Germany 2009 PMW, men, GIOP 7 10
Greece 2009–12 PMW, men, GIOP 5 8
Hungary 2003–11 PMW, men, GIOP 5 8
Ireland 2011 PMW, men 1 3
Italy −2011 PMW, men, GIOP 7 10
Latvia 2011 PMW, men, GIOP 7 10
Lithuania 2011 PMW 7 7
Luxemburg 2010 PMW 7 7
Malta na – 0 0
Netherlands 2011–12 PMW, men, GIOP 7 10
Poland 2011–12 PMW, men, GIOP 3 6
Portugal 2011 PMW 7 8
Romania 2011 PMW, men, GIOP 6 9
Slovakia 2006–10 PMW, GIOP 7 9
Slovenia 2002 PMW 2 3
Spain 2004–11 PMW, men, GIOP 4.5 6.5
Sweden 2008 PMW, men, GIOP 7 10
UKb 2008 PMW, men, GIOP 7 10
a PMW postmenopausal women, GIO glucocorticoid-induced
osteoporosis
b Relates to guidance provided by the National Osteoporosis
Guidelines Group [4]. National guidance with less scope also available
from NICE [5–7]
Table 36 Criteria for allocating scores
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Methods
Data were acquired by an IOF questionnaire to the EU
Osteoporosis Consultation Panel undertaken in Decem-
ber 2012. Respondents were asked whether national
guidelines were available for the assessment and/or
treatment of osteoporosis. Responses were used to
update an earlier audit of the IOF [1, 2]. Where
guidelines were available, additional information was
requested on their scope and quality.
Scope of guideline: Does it relate to postmenopausal women
(PMW), men or glucocorticoid-induced osteoporosis (GIOP).
AGREE criteria: The quality of guidelines was judged
according to the criteria developed the Appraisal of
guidelines for research & evaluation (AGREE) next steps
consortium [3] under 7 general domains (see footnote1).
Results
Guidelines for the management of osteoporosis were available
in the majority of member states (unavailable in Cyprus and
Malta). All of the remaining counties had guidelines available
for postmenopausal women (Table 35). 17 of 25 countries had
guidelines for osteoporosis in men and 19 had guidelines for
glucocorticoid-induced osteoporosis. The availability of
guidelines does not necessarily improve disease management
and in some countries (e.g. Italy, Spain and UK) multiple
guidelines were available from different sources that are likely
to confuse rather than clarify clinical practice.
Score criteria
A positive response in each AGREE category contributed a
point to the score (maximum 7 points). Up to 3 additional
points was given for the scope of the guideline (PMW, men,
GIOP) to give a maximum score of 10. Where more than one
guideline was available, a composite mean was used. Scores
for each country were categorised as shown in Table 36.
Score allocation
The score allocation and grade for each country is shown in
Fig. 25.
Comment
There was a large variation in the extent and quality of
national guidelines according to the AGREE criteria. It
should be noted that a high score reflects the quality of the
process, but not necessarily the quality of the content.
1 AGREE criteria
Systematic search. How thorough was the evidence base? Were
the guidelines based on a systematic literature review conducted at the
time of the guideline development (or on a previously conducted
review that was updated).
Recommendations: Were recommendations graded (e.g. A, B, C)
according to the levels of evidence provided by the systematic review?
Stakeholder involvement: Was there involvement from patient
organisations, primary care physicians, national/EU societies in the
consultation process for the guidelines?
External review: Were the guidelines reviewed by independent
experts? i.e. have they undergone a rigorous external review in
addition to consultation.
Procedure for update: Were the guidelines updated as and when
necessary or was there explicit mention of a provision to update the
guidelines in the future?
Economic analysis: Were the recommendations underpinned by
an economic analysis?
Editorial independence: Did the guidelines explicitly state that
there was editorial independence of the writing group from any
funding body?
Fig. 25 Score allocation based
on the scope and quality of
guidelines available for the
assessment and treatment of
osteoporosis. For the UK (star),
the score for guidance provided
byNICE is 8 and hat provided by
the National Osteoporosis
Guidelines Group has a score of
10 [IOF audit]
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3f Guideline criteria for assessment and treatment
Domain
Service provision—supplementary information
Background and aims
The aim of this section was to summarise the differences
in the application of guidelines to clinical practice and,
in particular, to identify where guideline recommenda-
tions conflicted with reimbursement policy.
Methods
A review was undertaken of guidelines covering the
assessment and treatment of osteoporosis in each EU member
state thatwas available inEnglish or French.Additionally, data
were acquired from a structured IOF questionnaire adminis-
tered to the EUOsteoporosis Consultation Panel undertaken in
December 2012. Information requested included whether
guidelines addressed population-based screening, the tools
used for assessment, and the tools to decide eligibility for
treatment. An enquiry was also made whether risk assessment
or treatment recommendations were compatible with reim-
bursement policy.
Results
Guidelines were not available in Cyprus or Malta. In the
remaining countries, guidelines were generally less than
5 years old, often related to updating, with one exception
(Slovenia, 2002).
Population screening was considered in guidelines from
15 of 25 countries. Although reviewed, population based
screening was not recommended. In Hungary, however
BMD is offered free of charge to women aged 50 years or
more, though the uptake is low.
Guidelines in 24 of the 25 countries covered the
assessment of fracture risk (the exception was the Czech
Republic). The most common tools used for fracture risk
assessment were age in 22/25 countries (exceptions were
Lithuania, Slovakia and Sweden) and bone mineral
density (in all countries). The use of fracture risk
assessment algorithms was less consistent and noted in
17 countries (Fig. 26). FRAX was the most widely used
instrument though in Germany the DVO tool was
recommended [1]. In the UK, both FRAX and QFracture
has been approved [2].
Guidelines in all 25 countries covered eligibility for
treatment with a general commonality of approach. Eligibility
for treatment depended on prior fracture (except Denmark and
Sweden), age (except Lithuania, Slovakia and Sweden) and
BMD (all countries). As was the case for assessment (see
Chapter 3d), risk assessment tools provided criteria for
intervention in fewer (17/25) countries (Fig. 26). In Italy,
Spain and the UK, there are several guidelines from
different sources that give different recommendations.
Several counties reported incompatibilities between
recommendations for risk assessment or treatment with
reimbursement policy (Table 37). For example, guidelines
Fig. 26 The distribution of the use of risk assessment models in
assessment guidelines of the EU27 countries [IOF audit]
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recommended the use of FRAX which was not provided for
in reimbursement provision (Belgium, Poland, Romania
and Slovakia), specific treatments were recommended but
not reimbursed (Poland, Romania) and central DXA was
recommended for risk assessment but other techniques
(peripheral BMD and QCT) were reimbursed (Lithuania). In
Luxembourg, the BMD thresholds for treatment differ from
the criteria for reimbursement for DXA. In other instances,
guidelines recommended the use of risk factors such as a
prior fragility fractures but reimbursement was solely
dependent on BMD (Lithuania, Romania). With regard to
treatment, reimbursement was limited in time (18 months)
but treatment recommended on a long-term basis
(Lithuania). A problem inconsistently related to reim-
bursement was that multiple guidelines gave conflicting
recommendations (Italy, Spain, and the UK). Another
barrier to treatment is that reimbursement was only
granted where the prescription was issued by a specialist
(e.g. Czech Republic).
Score allocation
Supplementary information, no score allocation
Comment
Risk assessment or treatment recommendations were
compatible with reimbursement policy in approximately
half of the EU member states.
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3g Fracture liaison services
Domain
Service provision—scorecard element
Background and aims
Fracture liaison services (FLS), also known as osteoporosis
co-ordinator programmes and care manager programs,
provide a system for the routine assessment and manage-
ment of postmenopausal women and older men who have
sustained a low trauma fracture [1–4]. Assessment includes
DXA measurements, fall risk evaluation, and underlying
secondary causes of osteoporosis. Although the importance
of an incident fracture as a risk factor for further fracture is
well recognised, the majority of patients presenting with a
low trauma fracture do not receive appropriate assessment
and treatment in the setting of standard hospital care. FLS
address this need through a systematic approach to
identifying such individuals and assessing their risk of
further fractures and the need for treatment. Most FLS are
based in secondary care although models in primary care
have also been described. The clinical and cost-
effectiveness of FLS has been demonstrated in several
centres [5–7].
Table 37 Scope of guidelines for patient assessment, treatment and
consistency with reimbursement policy [IOF audit]
Date Assessment Compatible/
consistent
Treatment Compatible/
consistent
Austria 2010 Yes Yes Yes Yes
Belgium 2005–11 Yes No Yes No
Bulgaria 2007 Yes No Yes No
Cyprus na – – – –
Czech
Republic
2003–10 No No Yes No
Denmark 2009 Yes Yes Yes
Estonia 2012 Yes Yes Yes Yes
Finland 2013 Yes Yes Yes Yes
France 2012 Yes Yes Yes Yes
Germany 2009 Yes No Yes No
Greece 2009 Yes Yes Yes Yes
Hungary 2011 Yes Yes Yes Yes
Ireland 2011 Yes No Yes Yes
Italy −2011 Yes Yes/no Yes No
Latvia 2011 Yes Yes Yes Yes
Lithuania 2011 Yes No Yes No
Luxembourg 2010 Yes No Yes Yes
Malta na – – – –
Netherlands 2011–12 Yes Yes Yes Yes
Poland 2011–12 Yes No Yes No
Portugal 2011 Yes Yes Yes Yes
Romania 2011 Yes No Yes No
Slovakia 2006/09/10 Yes No Yes Yes
Slovenia 2002 Yes Yes Yes Yes
Spain 2004–11 Yes/no Yes/no Yes/no Yes
Sweden 2012 Yes Yes Yes Yes
UK 2008–12 Yes Yes/no Yes Yes
na not applicable, nr not recorded
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The aim of this scorecard element was to document the
proportion of hospitals that have a fracture liaison service in
the EU27 countries.
Methods
Information was acquired from a structured IOF
questionnaire administered to the EU Osteoporosis
Consultation Panel undertaken in December 2012.
Correspondents were asked to estimate the proportion
of hospitals in each member state that have a scheme in
place that refers fracture patients over 50 years old to a
fracture liaison service. Scoring was based on the
distribution of the estimates.
Results
No estimates were provided from Malta. Of the remaining
countries, no fracture liaison services were reported from
Greece, Latvia, Portugal, Romania and Slovakia. The
presence of FLS was acknowledged in the remaining
member states, but for most countries, the proportion of
hospitals that have a scheme in place was less than 10 %.
Higher rates were reported from Austria, Cyprus, Czech
Republic, Estonia, Finland, Hungary, Netherlands and
Sweden (Fig. 27).
Score criteria
The proportion of hospitals in each member state that had
fracture liaison services (FLS) in place were categorised as
shown in Table 38.
Score allocation
Figure 28 shows the scores allocated by country
Comment
The information provided needs to be interpreted cautious-
ly. It provides a perception of how many hospitals of a
country has a fracture nurse working in a fracture liaison
service, but is an expert opinion and not based on numerical
evidence. Moreover, no account was taken of FLS in
primary care. In addition, no information was available on
the performance of the FLS. It is also notable that a colour
code of green should not be interpreted as an endorsement
since provision should, in the view of the panel, be expected
in the majority of hospitals or care centres.
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Fig. 27 The proportion of hospitals (%) with FLS in the EU countries
[IOF audit]
Table 38 Criteria for allocating scores
Fig. 28 Scores allocated by country on the availability of fracture
liaison services in hospitals by member state [IOF audit]
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3h Use of quality indicators
Domain
Service provision—scorecard element
Background and aims
The use of indicators to systematically measure the quality of
care provided to people with osteoporosis or associated
fractures is a relatively new discipline, with the United States
perhaps having the most developed system in place [1], as
shown for use of healthcare quality indicators more broadly
[2]. In the UK, the Department of Health Best Practice Tariff
for hip fracture care has used financial incentives since April
2010 to drive adherence with the six core benchmarks, which
include an assessment of bone health and risk of falling. In the
2 years following introduction of the tariff, the proportion of
patients with fragility hip fracture for whom all six standards
were met rose from 24 to 55 % [3].
The aim of this scorecard element was to document the
systematic approaches to enhance the quality of osteoporosis
care or secondary prevention of fragility fractures in the EU.
Methods
Data were acquired by an IOF questionnaire to the EU
Osteoporosis Consultation Panel undertaken in December
2012. Respondents were asked whether national systems were
in place that systematically collect data on the quality of care
provided to people with osteoporosis or the secondary
prevention of fragility fractures. Further questions were
whether the systems use measures (quality indicators or
standards) that are documented on a regular basis (e.g.
annually) and use a set of explicit criteria to assess performance.
Results
Few countries had systems that include quality measures
plus a regular audit for national health care agencies
(Denmark, Germany, and UK). In the United Kingdom,
osteoporosis/ secondary prevention of fragility fractures has
been included in the Quality and Outcomes Framework as
part of the general practitioner contract from April 2012 [4].
The Quality and Outcomes Framework is a pay for
performance scheme for general practice in the UK, which
awards ‘achievement points’ for adhering to procedural and
treatment guidelines and meeting intermediate outcome
targets for over 130 quality indicators. In the UK, there is
also a system of clinical audits in place, seeking to improve
patient care and outcomes through systematic review of care
according to explicit criteria and the implementation of
change. These include the National Audit of Falls and Bone
Health in Older People [5] and the continuous National Hip
Table 39 Systems that provide quality indicators in the context of
osteoporosis and fractures in the European Union [IOF audit]
Systems in place Targets Score
Austria No 1
Belgium No 1
Bulgaria Yes Hip fractures 2
Cyprus No 1
Czech Republic No 1
Denmark Yes Hip fractures 3
Estonia No 1
Finland Yes Hip fractures 2
France No 1
Germany Yes Hip fractures 3
Greece Yes Hip fractures 2
Hungary Yes Fragility fractures 2
Ireland No 1
Italy No 1
Latvia No 1
Lithuania No 1
Luxemburg No 1
Malta No 1
Netherlands Yes 3
Poland No 1
Portugal No 1
Romania No 1
Slovakia Yes Osteoporosis, fragility
fracture, falls
2
Slovenia No 1
Spain No 1
Sweden Yes Fractures, treatment 2
UK Yes Hip fracture, falls,
fragility fractures
3
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Fracture Database [3]. In Germany, selected providers and
health insurance funds have, in the framework of ‘integrated
care contracts’ entered into agreements on coordinated
osteoporosis care which may include the documentation of
care standards to enable tracking of the quality of care
provided. The nature and contents of these contracts vary
across regions [6]. There is a systematic and nationwide
collection of quality indicators for the inpatient care
following hip fracture [7]; however a systematic collection
of indicators that would permit assessment of care quality of
those with osteoporosis and in the secondary prevention of
fragility fractures is not in place.
Several other counties (Bulgaria, Finland, Greece)
have systems that provide quality indicators or standards
that are documented on a regular basis (Table 39) but it
is unclear whether criteria are developed to assess
performance. In Slovakia, quality measures are in place
but no provision is made for regular audit.
Score criteria
The score was based on the presence of systems and their
use as quality indicators as given in Table 40
Score allocation
Score allocation for quality indicators by country are given in
Fig. 29.
Given the relative novelty of using QI for the
tracking of quality of care provided to people with
osteoporosis or associated fractures in the European
region, it should be recognised that the score is a
‘proxy’ measure. Though audited quality measures have
been introduced in some countries, the UK is far advanced in
this regard.
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Fig. 29 Score allocation for quality indicators by country [IOF audit]
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Chapter 4. Service uptake
4a Uptake of DXA
Domain
Service uptake—background information
Background and aims
The ability to assess osteoporosis depends in part on the
availability of bone mass measurements at the lumbar
spine and hip with dual energy X-ray absorptiometry
(DXA). The requirement for the technology will depend
on the assessment guidelines in each member state and
the policy with respect to the use of DXA to diagnose
osteoporosis and monitor treatment. The uptake of this
technology depends upon the efficiency with which the
technology is used, the ease of patient access (e.g.
travelling time), regulatory constraints and barriers to
reimbursement.
The aim of this element was to compare the access to
DXA measured as a function of the requirements
recommended in relevant assessment guidelines.
Methods
Ideally, uptake should be measured as the number of scans
undertaken in relation to treatment guidelines in each
member state. Such data are not available in the EU as a
whole. Data are available by age and sex from the National
Health Service of Denmark and are reported here
[Abrahamsen, 2011].
Results
The Danish National Health Service release claims data for
DXA and was available most recently for 2005. The uptake of
BMD testing by age and sex for 2005 is shown in Fig. 30.
Although the accuracy of the claims to tests is uncertain and
tests in the private sector are not captured, the uptake was very
low even accounting for these errors. Thus, guidelines based
on BMD testing indicate that 173 women/1,000 women aged
50 years or more qualify for BMD testing [2] whereas the
corresponding figure for Denmark was 28.6 or 16 % of the
desired uptake. The use of probability-based guidelines
reduces the number of scans needed to 81/1000 women [2]
but is still considerably higher than that attained in Denmark.
The uptake in men over the age of 50 years was 4 times lower
(7/1000) than in women. In men and women combined the
uptake of DXAwas 18.5/1000.
Score allocation
No score allocation
Comment
More information is required from all member states on the
utilisation of DXAwith regard to guidelines on the assessment
and monitoring of treatment. The available evidence from
Denmark, a country moderately provided with DXA ma-
chines, is that service uptake is less than optimal.
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Fig. 30 The uptake of BMD testing in men and women by age and
sex in Denmark in 2005 [Data kindly provided by Bo Abrahamsen,
Gentofte Hospital Copenhagen, Denmark]
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4b Uptake of risk assessment algorithms
Domain
Service uptake—scorecard element
Background and aims
FRAX is an algorithm that determines fracture
probability in individuals by integrating the weight
of important clinical risk factors for fracture and
mortality risk, with or without information on
BMD (see Chapter 1 g). Each tool is country-specific
and calibrated to the national epidemiology of fracture.
They were developed by the WHO Collaborating
Centre for Metabolic Bone Diseases at Sheffield,
UK and launched in 2008 [1, 2]. The FRAX
tools (www.shef.ac.uk/FRAX) compute the 10-year
probability of hip fracture or a major osteoporotic
fracture. A major osteoporotic fracture is a clinical
spine, hip, forearm and humerus fracture. The use of the
tool improves risk assessment compared to the use of
BMD alone.
FRAX is now a component of many national guidelines
for the assessment of osteoporosis (see Chapter 3f) and
European guidelines for postmenopausal osteoporosis and
glucocorticoid-induced osteoporosis [3, 4]. The aim of this
element was to determine the usage of FRAX in the EU27
countries.
Methods
Each FRAX model on the web counts the number of
calculations performed for that particular country. A
problem with these data is that some countries,
particularly those without a country-specific FRAX
model, may use a surrogate. For example, the UK
model was adopted as a surrogate in Poland before the
advent of a Polish model and the Greek model is
presently used in Cyprus. For this reason, we assessed
the number of calculations by the source of the
calculation [Google Analytics]. FRAX usage was
computed as the number of calculations originating
f r o m e a c h c o u n t r y a n d e x p r e s s e d a s
calculations/million of the general population over a
period of one year (November 2010 to December
2011).
Results
The web-based usage of the models is shown in Table 41
which shows considerable heterogeneity in uptake. Bel-
gium, UK, Luxembourg, Sweden and Ireland have the
highest usage of FRAX. Lithuania, Latvia, Germany and
Bulgaria have the lowest uptake. The average uptake for the
EU27 was 880 calculations/million of the general
population.
Country-specific models are available in 21 member
states (see Chapter 3d). FRAX models are not available
for Bulgaria, Cyprus, Estonia, Latvia, Luxembourg and
Slovenia. There is, however, no clear relationship
between the availability of a country-specific model
and the use of FRAX.
Score criteria
FRAX ca l c u l a t i o n s /m i l l i o n o f t h e g en e r a l
population/year was categorised by tertiles as given in
Table 42
Table 41 Uptake of FRAX in
EU counties expressed as the
number of calculations per mil-
lion of the general population
Country Calculations
/million
Country Calculations
/million
Country Calculations
/million
Austria 1534 Germany 83.5 Netherlands 526
Belgium 5003 Greece 502 Poland 338
Bulgaria 112 Hungary 1205 Portugal 1039
Cyprus 272 Ireland 1643 Romania 230
Czech Republic 175 Italy 518 Slovakia 372
Denmark 942 Latvia 57.7 Slovenia 1322
Estonia 207 Lithuania 28.5 Spain 1115
Finland 444 Luxembourg 2293 Sweden 1911
France 314 Malta 1541 UK 2293
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Score allocation
Countries, ranked and categorised by score, are shown in
Fig. 31.
Comment
These data underestimate the use of FRAX by approximately
25 % due to the availability of FRAX on bone densitometers.
FRAX calculations on densitometers are not performed
through the web site. In addition, hand held calculators are
used in several countries, particularly in Poland. FRAX is also
available as an application on the iPhone.
These data underestimate the use of risk assessment in
Germany. Fracture risk assessment comprises a component of
the German national guidelines, but is not FRAX based.
Alternative assessment algorithms are also available in the UK
and the Netherlands.
The caveats above indicate that the figures are conservative.
Even so, there are reasons to believe that FRAX is underutilised.
For example, the use of FRAX in Denmark (942
calculations/million per year) is much lower than the number
of BMD tests/year (18,500 /million per year; see Chapter 4a).
Thus, a colour code of green should not be interpreted as an
endorsement of appropriate uptake.
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4c Treatment uptake and treatment gap
Domain
Service uptake—scorecard element
Background and aims
Many surveys indicate that a minority of men and women at
high fracture risk receive treatment [1, 2]. The aim of this
section was to estimate the proportion of women at high risk
that receives therapy for osteoporosis in the EU27.
Methods
The proportion of patients eligible for treatment depends
on defining an intervention threshold, i.e. the risk of
fracture above which treatment can be recommended.
Though treatment guidelines are available in nearly all
EU member states [3] (see Chapters 3e and 3f), there is
no uniform approach to intervention thresholds across
the EU27.
The advent of FRAX (www.shef.ac.uk/FRAX) in
2008 provided a clinical tool for the calculation of
Fig. 31 The uptake of fracture risk assessment tools as judged by the
use of FRAX from each EU country by score category. *See comment
below with regard to Germany
Table 42 Criteria for allocating scores
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fracture probability that has been applied to the
development of intervention thresholds [4]. For the
purposes of this analysis, the intervention threshold set
was at the 10-year fracture probability equivalent to
women with a prior fragility fracture without knowledge
of BMD as adopted in several European guidelines [5–
7]. Thus, the intervention threshold can be likened to a
‘fracture threshold’ expressed in terms of fracture
probability. The proportion of women who exceed the
fracture threshold was computed by simulation [8] based
on the distribution of the risk-score among the cohorts
used by WHO to develop FRAX and the epidemiology
of fracture and death in each EU country.
The number of patients treated in each country was
computed from IMS Health sales data for 2010 and
expressed as treatment years [3]. The use of hormone
replacement treatment was excluded since the majority
of women take hormone replacement treatment for
menopausal symptoms rather than for osteoporosis. An
adjustment factor (estimated from data from the Swedish
Prescribed Drug Register) was used to correct for
suboptimal adherence. The number of women potentially
treated was subtracted from the number of women
exceeding the intervention threshold and expressed as a
percentage. No sales data were available for Cyprus or
Malta and these two countries were therefore excluded
from analyses.
Results
Table 43 indicates that there is wide inter-country
variation in the treatment penetration of women at high
risk for osteoporotic fractures. The treatment gap varied
from 25 % in Spain to 95 % in Bulgaria. Large
treatment gaps were identified in countries with
populations at both high and low risk of fracture. In
total in the EU, it is estimated that, out of the 18.4
million women that exceed the risk level, 10.6 million
are untreated. These figures are conservative since an
undetermined proportion of low-risk women will have
received treatment (see comments, below).
Table 43 Number of women
eligible for treatment, treated
and treatment gap in 2010 [3]
Country Number potentially
treated (000s)
Number exceeding fracture
risk threshold (000s)
Difference (000s) Treatment gap (%)
Austria 139 282 143 51
Belgium 214 402 188 47
Bulgaria 13 240 227 95
Czech Republic 79 330 251 76
Denmark 87 190 103 54
Estonia 7 48 41 86
Finland 53 172 119 69
France 1,390 2,437 1,047 43
Germany 730 3,231 2,501 77
Greece 333 482 149 31
Hungary 238 332 94 28
Ireland 91 124 33 26
Italy 1,069 2,635 1,566 59
Latvia 12 80 68 85
Lithuania 11 109 98 90
Luxembourg 9 16 7 43
Netherlands 242 605 363 60
Poland 245 1,127 882 78
Portugal 269 425 156 37
Romania 100 599 499 83
Slovakia 75 148 73 49
Slovenia 35 62 27 44
Spain 1,277 1,709 432 25
Sweden 100 358 258 72
UK 1,064 2,298 1,234 54
EU27 7,881 18,441 10,560 57
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Score criteria
Countries were categorised by approximate tertiles as
shown in Table 44.
Score allocation
The score allocation and the treatment gap for each country
is shown in Fig. 32.
Comment
It is unlikely that 100%of sales are captured in any country but
it is difficult to define the magnitude of underestimation. IMS
Health attempts to correct for under- and over-estimation, and
in the absence of any additional information, there is no further
adjustment of the available sales figures.
Another difficulty in interpretation may arise from
parallel trade. IMS Health adjusts the data for parallel trade
in some countries. The countries for which adjustments
have been made are Austria, Belgium, Czech Republic,
Denmark, Finland, France, Germany, Italy, the Netherlands,
Poland, Spain, Sweden and the UK.
The pattern of use within countries cannot be ascertained
in this analysis, so that it is not possible to determine
whether treatment is targeted appropriately to high risk
individuals. There are several indicators that suggest that the
targeting of treatment is heterogeneous in the EU27. Good
evidence comes from the Global Longitudinal Study of
Osteoporosis in Women (GLOW) which is a general
practice based observational cohort study in women aged
55 years or more conducted in 10 countries, including
several EU countries [1]. In the EU countries, there was
heterogeneity of treatment uptake between countries with
the lowest proportion of women aged 55 years or more
treated in the Netherlands (7 %) and the highest in Spain
(23 %) (Fig. 33). Although treatment uptake was higher in
women at very high risk (a prior hip or spine fracture), a
minority (45 %) were receiving treatment in these countries.
Again, there was heterogeneity in treatment uptake that
ranged from 36 % in the Netherlands to 57 % in Italy.
Moreover, some low-risk women were targeted in all
countries.
These data demonstrate that a large number of women
at high risk of fractures are not receiving treatment, that
a substantial number of women at low risk are
prescribed treatment (13–22 %) and confirm important
differences in the uptake of treatment between countries.
Thus, a colour code of green should not be interpreted
as an optimum.
Table 44 Criteria for allocating scores
Fig. 32 Proportion of women of women at high risk that are untreated
(treatment gap) in 2010 ranked by country and score [3]
Fig. 33 Proportion of women receiving treatment in six EU member
states according to category of risk. All women refer to women aged
55 years or more (n=24,249). Low risk comprises women aged less
than 75 years with a T score for BMD in the range of osteopenia, no
prior fracture, no maternal hip fracture or osteoporosis (n=1166). High
risk refers to women reported to have a BMD measurement in the
range of osteoporosis (n=5258). Very high risk comprises women with
a previous hip or spine fracture (n=913) [9]
144, Page 52 of 63 Arch Osteoporos (2013) 8:144
References
1. Díez-Pérez A, Hooven FH, Adachi JD et al. (2011) Regional
differences in treatment for osteoporosis. The Global Longi-
tudinal Study of Osteoporosis in Women (GLOW). Bone 49:
493–8.
2. Guggina P, Flahive J, Hooven FH et al. (2012) Characteristics
associated with anti-osteoporosis medication use: Data from
the Global Longitudinal Study of Osteoporosis in Women
(GLOW) USA cohort. Bone 51: 975–980
3. Hernlund E, Svedbom A, Ivergård M Compston J, Cooper C,
Stenmark J, McCloskey EV, Jönsson B, Kanis JA (2013)
Osteoporosis in the European Union: Medical Management,
Epidemiology and Economic Burden. A report prepared in
collaboration with the International Osteoporosis Foundation
(IOF) and the European Federation of Pharmaceutical Industry
Associations (EFPIA). Arch Osteoporos, in press
4. Kanis JA, Hans D, Cooper C, et al. (2011) Interpretation and use
of FRAX in clinical practice. Osteoporos Int 22: 395–411
5. Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D,
McCloskey EV, Reid DM, Selby P, Wilkins M; on behalf of the
National Osteoporosis Guideline Group (NOGG) (2009) Guide-
lines for the diagnosis and management of osteoporosis in
postmenopausal women and men from the age of 50 years in
the UK. Maturitas; 62:105–108.
6. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R,
Reginster J-Y on behalf of the Scientific Advisory Board of the
European Society for Clinical and EconomicAspects of Osteoporosis
and Osteoarthritis (ESCEO) and the Committee of Scientific
Advisors of the International Osteoporosis Foundation (IOF) (2013)
European guidance for the diagnosis andmanagement of osteoporosis
in postmenopausal women. Osteoporos Int 24: 23–57.
7. Lekawasam S, Adachi JD, Agnusdei D et al. for the Joint IOF-
ECTS GIO Guidelines Working Group (2012) A framework for
the development of guidelines for the management of
glucocorticoid-induced osteoporosis. Osteoporos Int 23:2257–76.
8. Kanis JA, Johansson H, Odén A, McCloskey EV (2012) The
distribution of FRAX® based probabilities in women from Japan.
J Bone Miner Metab 30: 700–5.
9. Hooven FH and the GLOW investigators (2012) Previously
unpublished data derived from Díez-Pérez et al., 2011 [1],
courtesy of F Hooven and the GLOW investigators
4d National prescription database
Domain
Service uptake—Background information
Background and aims
IMS Health provides sales data that can be examined by
country but give no information on who receives the agent in
question or the purpose for which it was given (see Chapter
4c). Such data are not available on an EU-wide basis.
However, several EU countries have a National Prescription
Database that can provide more detailed information.
Methods
The National Prescription Databases of Sweden was
accessed to determine the number of individuals by age
who had received a prescription for a bone-active
medication in 2010. Exposure to oestrogens was not
included. Treatment days (daily defined doses; DDD)
were computed from the prescription refills in 2010 and
converted to person-years of exposure to treatment
(DYD). Treatment rates were expressed as a proportion
of the Swedish population [1].
Results
The numbers of individuals by age who had received bone-
active medication and the DYDs are shown in Table 45.
Treatment uptake is expressed as the number of individuals
who were taking a bone-active medication (i.e. filled a
prescription) and the number of person-years of treatment in
that year. For example, there were 18,931 men and women
aged 80–84 years who had been prescribed a treatment in
2010. The total prescription base for that age range was
equivalent to 13,888 person-years. Over all ages, 3 % of the
Swedish population aged 50 years or more received treatment.
Figure 34 shows the uptake of bone-active agents
(oestrogens excluded) for 2010. For example, there
were 77 prescriptions filled per 1,000 of the population
aged 80–85 years in 2010. The number of unique
patients that received a prescription for that age range
was 56 per 1,000 person-years. These figures are low
when compared with the population at high risk. For
example, the number of patients in this age range that
received a treatment was approximately 13,500 representing
Table 45 Population size, patients treated and patient-years of
treatment by age in Sweden 2010
Age
(years)
Population
(000)
Patients
treated
Patient-years of
treatment
DYD
50–54 577 2,347 1,779 1,779
55–59 573 5,328 3,953 3,953
60–64 626 10,346 7,665 7,665
65–69 535 15,685 11,693 11,693
70–74 378 17,081 12,659 12,659
75–79 303 18,802 14,055 14,055
80–84 247 18,931 13,888 13,888
85+ 249 16,883 12,394 12,394
50+ 3,488 105,403 78,086
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5.6 % of the population at this age. In contrast, the number of
individuals in this age range with osteoporosis is estimated at
67,800 and those with a fracture probability above a fracture
threshold is estimated at 32,000 [2]. Thus, although treatments
are targeted by age, the majority of high risk individuals
remain untreated.
Score allocation
None—supplementary information
Comment
Note that the data do not give information on
persistence or compliance. Although treatments are
targeted by age, the majority of high risk individuals
remain untreated.
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4e Treatment gap and treatment need
Domain
Service uptake—Background information
Background and aims
Patients who sustain a prior fragility fracture are at great risk of
a future fracture. The risk is increased approximately two-fold
[1] and is largely independent of BMD [2]. The risk is
sufficiently high that many treatment guidelines in the EU
recommend that postmenopausal women with a prior fragility
fracture should be offered treatment. However, the majority of
such patients are untreated so that the prevalence of a prior
fracture in the community provides an index of opportunity
lost. This may be set against the treatment gap to provide an
index of the relationship between service provision and service
need. The aim of this element was to provide an index of the
prevalence of a prior fracture in the EU member countries in
relation to the treatment gap.
Methods
For the purposes of this report, a prior fracture was defined
as a hip or clinical vertebral fracture in an individual who
was alive in 2010 that had occurred after the age of 50 years
before 2010. The unit was the individual so that multiple
fractures at the same site in one individual were only
counted as one prior fracture of that site. A micro-
simulation model, programmed in TreeAge, was used to
simulate the prevalence of prior hip and vertebral fractures
from incidence data [3]. Note that the prevalence of a hip or
clinical vertebral fracture will underestimate the prevalence
of previous fragility fracture at other sites.
More complete information on prior fractures is available for
six member states (France, Germany, Italy, Spain, Sweden and
the UK) using a different approach [4] and is also considered.
For the treatment gap, the data from Chapter 4c were
used [1].
Results
In 2010, approximately 6.7 million men and women in the
EU had sustained a prior hip or clinical spine fracture before
2010 (Table 46). As would be expected, the prevalence
increased progressively with age. At the age of 95 years or
more, the prevalence of a prior hip fracture was 22.5 % and
for a prior vertebral fracture was 14.5 % [1]. Overall, 1.8 %
of the population at the age of 50 years or more had a prior
hip fracture and 1.9 % a prior clinical spine fracture.
Fig. 34 The number (rate/thousand) of prescriptions for bone-active
medications and the number of patients filling a prescription for bone-
active medications in 2010 [National Prescription Databases of
Sweden]
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The ranked prevalences by country are shown in Fig. 35.
As would be expected, there was a close relationship
between fracture risk (see Chapter 1b) and the proportion of
the population with a prior hip or clinical vertebral fracture.
Table 47 summarises data for the EU5+Sweden which
shows the prevalence of all prior fractures in 2010 in
comparator studies. The estimation of prior vertebral + prior
hip fracture, shown in Fig. 35, appears to capture approximately
30 % of prior fractures. This suggests that the prevalence of a
prior clinical spine or hip fracture is a reasonable surrogate for
the service needs of each member state.
The relationship between this service need and the
treatment gap is shown in Fig. 36 for each of the EU
member states and for the EU countries combined. The
top right quadrant can be considered to represent
countries of high need but poor provision. These
included Denmark and Sweden. The other extreme
(lower left quadrant) represents countries of lower need
Table 46 Estimated number
and percentage of men and
women aged above 50 years
with a prior hip or vertebral
fracture by country in 2010 [3]
Hip fracture Vertebral fracture A+B
Number % Population (A) Number % Population (B)
Austria 74,270 2.4 83,623 2.7 5.1
Belgium 74,485 1.9 80,706 2.0 3.9
Bulgaria 31,370 1.1 32,780 1.1 2.2
Cyprus 4,921 1.6 6,150 2.0 3.6
Czech 58,979 1.6 64,340 1.7 3.3
Denmark 49,746 2.5 58,573 2.9 5.4
Estonia 7,350 1.5 7,486 1.5 3.0
Finland 34,181 1.6 37,192 1.8 3.4
France 434,674 1.9 435,507 1.9 3.8
Germany 669,799 2.0 775,529 2.3 4.3
Greece 87,413 2.1 101,760 2.4 4.5
Hungary 57,225 1.6 60,594 1.6 3.2
Ireland 17,247 1.4 18,742 1.5 2.9
Italy 517,126 2.2 539,036 2.3 4.5
Latvia 11,862 1.5 11,575 1.4 2.9
Lithuania 13,046 1.2 12,782 1.1 2.3
Luxemburg 2,446 1.5 2,790 1.8 3.3
Malta 1,974 1.3 2,316 1.5 2.8
Netherlands 74,594 1.3 82,206 1.4 2.7
Poland 139,212 1.0 144,863 1.1 2.1
Portugal 52,106 1.3 53,653 1.4 2.7
Romania 72,024 1.0 82,829 1.1 2.1
Slovakia 28,065 1.6 32,488 1.9 3.5
Slovenia 12,429 1.6 14,306 1.9 3.5
Spain 210,560 1.3 212,428 1.3 2.6
Sweden 98,952 2.8 111,348 3.2 6.0
UK 418,881 1.9 437,499 2.0 3.9
EU27 3,254,939 1.8 3,503,101 1.9 3.7
Fig. 35 The proportion (%) of the population aged 50 years or more
with a prior hip or vertebral fracture in 2010 [3]
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but better provision. These included Estonia, Ireland
Hungary and Spain.
Score allocation
Supplementary information, no score allocation
Comment
There is a wide variation in both (hip and spine) fractures
and treatment gap between countries. This is of particular
concern in countries with a high fracture burden and a high
treatment gap.
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4f Waiting time for hip surgery
Domain
Service uptake—scorecard element
Background and aims
About 5 % of people with a hip fracture die within
1 month and about one quarter within 12 months. Most
Fig. 36 The relationship between the prevalence of a prior spine or
hip fracture (service need) and the treatment gap (service provision) in
the EU27 countries. The horizontal and vertical lines intersect at the
EU average (weighted for population size) [3]. Country codes (ISO
3166–1 alpha-2); AT Austria; BE Belgium; BG Bulgaria; CY
Cyprus; CZ Czech Republic; DE Germany; DK Denmark; EE
Estonia; ES Spain; FI Finland; FR France; GB United Kingdom;
GR Greece; HU Hungary; IE Ireland; IT Italy; LT Lithuania; LU
Luxembourg; LV Latvia; MT Malta; NL Netherlands; PL Poland;
PT Portugal; RO Romania; SE Sweden; SI Slovenia; SK Slovakia
Table 47 The prevalence (%) of a prior fracture at sites associated
with osteoporosis in men and women aged 50 years or more compared
with the prevalence of a prior vertebral or hip fracture as given in Table
46. The last column shows the proportion (%) of prior fractures
accounted for by hip or clinical vertebral fracture [3]
Country Author Prevalence (%) EU/C
Comparator EU27
France Cawston 2012 [5] 11.2 3.8 34
Germany Gauthier 2012 [6] 14.1 4.3 30
Italy Piscitelli 2012 [7] 16.2 4.5 28
Spain Gauthier 2012 [8] 8.9 2.6 29
Sweden Gauthier 2011 [4] 22.6 6.0 27
UK Gauthier 2011[9] 10.3 3.9 39
Average 30
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deaths are due to associated conditions and not to the
fracture itself [1], reflecting the high prevalence of co-
morbidity. In the EU27, hip fractures were estimated to
result in approximately 11,000 premature deaths in
women that were directly attributable to the fracture
event in 2010. The corresponding numbers for men were
estimated at approximately 9,000 [2]. A determinant of
peri-operative morbidity and mortality is the time a
patient takes to get to surgery which, in turn, is an early
marker of a patient’s progress following a hip fracture.
Early surgery (<48 h) is associated with a statistically
and clinically significant reduction in mortality at 1 year
and an increase in the proportion of patients returning to
their original residence [3].
The aim of this scorecard element was to determine
average waiting times for hip surgery in the EU member
states.
Methods
Data were acquired by an IOF questionnaire to the EU
Osteoporosis Consultation Panel undertaken in December
2012. Respondents were asked to provide information on the
average waiting time for hip surgery after hip fracture.
Countries were categorised according to averagewaiting times
between hospital admission and surgical intervention. An
additional indicator of management that was sought was the
proportion of hip fracture cases that were managed surgically.
Results
Waiting times between admission to hospital and
surgical intervention were on average 1 day or less in
7 countries, 1–2 days in 13 countries and greater than
2 days in 6 countries (Table 48). Information was not
recorded for Malta. More than 90 % of hip fracture
cases received surgery in the majority of countries.
Exceptions included Bulgaria, Czech Republic, Hungary
and Italy where 75–90 % of cases received a surgical
intervention.
Score criteria and allocation
Uptake was categorised by average waiting time for hip
surgery (Table 49)
Score allocation
Score results are given in Table 48 and colour coded in Fig.
37.
Comment
Note that average waiting times give no index of the
dispersion around the mean
Table 48 Average waiting times between hospital admission and
surgical intervention and the proportion of hip fracture cases managed
surgically [IOF audit]
Waiting time
(days)
Surgical management
(%)
Score
Austria 1–2 >90 2
Belgium <1 >90 3
Bulgaria 1–2 75–90 2
Cyprus 2–3 >90 1
Czech
Republic
1–2 75–90 2
Denmark 1–2 >90 2
Estonia <1 >90 3
Finland 1–2 >90 2
France 1–2 >90 2
Germany <1 >90 3
Greece 2–3 >90 1
Hungary <1 75–90 3
Ireland 2–3 >90 1
Italy 2–3 75–90 1
Latvia <1 >90 3
Lithuania <1 >90 3
Luxembourg 1–2 >90 2
Malta nr nr
Netherlands 1–2 >90 2
Poland 1–2 >90 2
Portugal 2–3 >90 1
Romania 1–2 >90 2
Slovakia 1–2 >90 2
Slovenia 1–2 >90 2
Spain 2–3 >90 1
Sweden <1 >90 3
UK 1–2 >90 2
nr, not recorded
Table 49 Criteria for allocating scores
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Fig. 37 Countries categorised by the average waiting time for surgical
intervention for hip fracture [IOF audit]
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The scorecard
SCOPE. The Scorecard for Osteoporosis in Europe, is an
innovative tool that allows health and policy professionals to
assess key indicators on the healthcare provision for
osteoporosis in countries and between counties within the EU.
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Scorecard key
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Austria Austrian Society for Bone and Mineral Research
(AUSBMR)
Action for Healthy Bones
Austrian Menopause Society
National Osteoporosis Patient Society Austria
Belgium The Royal Belgian Rheumatology Society
Belgian Bone Club
Bulgaria Bulgarian Society for Clinical Densitometry
Association Women without Osteoporosis
Bulgarian League for the Prevention of
Osteoporosis-blpo
Bulgarian Medical Society of Osteoporosis and
Osteoathrosis
Cyprus Cyprus Society for Osteoporosis
Cyprus Society against Osteoporosis and Myoskeletal
Diseases
Czech
Republic
Osteologic Academy zlin
Czech Osteoporosis League
Czech Society for Metabolic Skeletal Diseases (SMOS)
Denmark National Osteoporosis Foundation Denmark
Danish Bone Society
Estonia Estonian Osteoporosis Society
Finland Finnish Bone Society
Finnish Osteoporosis Association
France French League Against Rheumatism (AFLAR)
French Society of Orthopaedic And Trauma Surgery
(SOFCOT)
French Society For Clinical Densitometry (SO.F.O.C.)
ResearchAnd InformationGroupOnOsteoporosis (GRIO)
Germany German Osteoporosis Patient Society (BFO)
Osteoporose Selbsthilfegruppen Dachverband E.V (OSD)
Netzwerk-osteoporose e.v
German Society For Endocrinology (DGE)
Committee For Healthy Bones– Kuratorium
Knochengesundheit
Orthopädische Gesellschaft Für Osteologie (OGO)
Greece Hellenic Society For The Study Of Bone Metabolism
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Hellenic Society Of Osteoporosis Patient Support
Hellenic Endocrine Society - Panhellenic Association
Of Endocrinologists
Hungary Hungarian Osteoporosis Patients Association (HOPA)
Hungarian Society For Osteoporosis And
Osteoarthrology
Ireland Irish Osteoporosis Society (IOS)
Italy Italian Association Of Osteoporosis Patients
Italian Foundation For Research On Osteoporosis And
Musculoskeletal Diseases - FIROMMS
Italian COPD Patient Association
Osteoporosis Italian Association - Osteo Stop
Italian Society For Osteoporosis Mineral Metabolism
And Skeletal Diseases (SIOMMMS)
Italian Federation Of Osteoporosis And Diseases Of
The Skeleton (FEDIOS)
Italian Osteoporosis League (LIOS)
Italian Society Of Rheumatology
Latvia Latvia Osteoporosis Patient And Invalid Association
Latvian Osteoporosis And Bone Metabolism Diseases
Association
Lithuania Lithuanian Osteoporosis Foundation
Lithuanian Association Of Metabolic Bone Diseases
Incorporated In Lithuanian Endocrine Society
Luxembourg Association luxembourgeoise d’étude du métabolisme
osseux et de l’ostéoporose (ALEMO)
Malta Malta Osteoporosis Society
Netherlands Osteoporose Vereniging
Osteoporose Stichting - Dutch Osteoporosis Foundation
Poland Healthy Bone Enthusiasts Society (STENKO)
Polish Foundation of Osteoporosis
Polish Osteoarthrology Society
Multidisciplinary Osteoporotic Forum
Portugal Portuguese Osteoporosis Association (APO)
Portuguese Society Of Osteoporosis And Other
Metabolic Bone Diseases (SPODOM)
National Association Against Osteoporosis (APOROS)
Romania Romanian Society Of Rheumatology
Association For Prevention Of Osteoporosis In
Romania (ASPOR)
Romanian Society Of Osteoporosis And
Musculoskeletal Diseases
Romanian Foundation Of Osteoarthrology (OSART)
Slovakia Slovak Union Against Osteoporosis
Slovak Society Osteoporosis & Metabolic Bone
Diseases
Slovenia Slovene Bone Society
Slovene Osteoporosis Patients Society
Spain Spanish Society for Rheumatology
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Spanish Society for Research on Bone and Mineral
Metabolism (SEIOMM)
Hispanic Foundation Of Osteoporosis And Metabolic
Bone Diseases (FHOEMO)
Spanish Association Against Osteoporosis (AECOS)
Spanish Society of Osteoporotic Fractures
Sweden 1.6 million club
Swedish Osteoporosis Patient Society (ROP)
Swedish Rheumatism Association
Swedish Osteoporosis Society
UK The Bone Research Society
National Osteoporosis Society (NOS)
Multinational International Osteoporosis Foundation (IOF)
Umbrella organisation of German speaking
osteoporosis patient societies (DOP)
Umbrella organisation of German speaking societies
of osteology (DVO)
European Society for Clinical and Economic Aspects
of Osteoporosis and Osteoarthritis (ESCEO)
Deustche Gesellschaft fur Osteologie
International Society For Fracture Repair (ISFR)
Mediterranean Society For Osteoporosis And Other
Skeletal Diseases (MSOSD)
Ibero American Society of Osteology and Mineral
Metabolism (SIBOMM)
European Union Geriatrics Medicine (EUGMS)
European Calcified Tissue Society (ECTS)
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Abbreviations and glossary
BMD Bone mineral density, usually measured
as the amount of calcium in bone per
unit area.
BMI Body mass index, an index of leanness
or obesity measured from height and weight
CI Confidence interval
CRF Clinical risk factor, in this context for
fracture
DALY Disability-adjusted life year, a product of
years of life lost and the remaining years
of life disabled (i.e., disutility).
DDD Defined daily dosage
Direct costs Used in health technology assessment
to describe direct healthcare costs
(e.g., hospital admissions, medical
examinations, drug therapy, etc.),
the indirect costs (e.g., losses in
productivity resulting from absence
to work) and intangible costs (e.g. pain
and suffering, poor quality of life).
DXA Dual-energy X-ray absorptiometry, a
method for measuring BMD
EFPIA European Federation of Pharmaceutical
Industries Association
EU27 The 27 member states of the European Union
FRAX Fracture risk assessment tool developed by
the WHO Collaborating Centre, University
of Sheffield Medical School, UK. FRAX
calculates the 10-year probability of a major
osteoporotic fracture and hip fracture in
individuals from clinical risk factors and
BMD
GDP Gross domestic product, the total value
of goods produced and services provided
in a country in 1 year
GLOW Global Longitudinal Study of Osteoporosis
in Women
ICD International classification of diseases
IMS Intercontinental Marketing Services
Incidence The frequency of an event, usually expressed as
a rate e.g. 10 per 1000 of the population/year.
IOF International Osteoporosis Foundation
mg Milligram
MPR Medication possession ratio
NHANES National Health and Nutrition Examination
Survey
NICE National Institute of Health and
Clinical Excellence
NOGG National Osteoporosis Guideline Group
Prevalence The number of cases of disease
(e.g. osteoporosis) for a given area or at
a given time
Probability The likelihood of an event, e.g. fracture.
Fracture probability depends on two
hazards—the incidence of fracture and
the incidence of death
QALY The QALY is a multi-dimensional outcome
measure that incorporates both the quality
(health related) and quantity (length) of life.
The value of a QALY was set at value of
2× GDP per capita
QCT Quantitative computed tomography
QoL Quality of life
QUS Quantitative ultrasound
SCOPE Scorecard for osteoporosis in Europe
SD Standard deviation
T score Describes the number of standard
deviations (SD) by which the BMD
in an individual differs from the
mean value expected in young healthy
144, Page 62 of 63 Arch Osteoporos (2013) 8:144
women. The operational definition of
osteoporosis is defined as a value for
BMD 2.5 SD or more below the young
female adult mean (T score less than or
equal to −2.5 SD).
WHO World Health Organization
WTP Willingness to pay, used in Health
Technology assessment to describe
the value that society or a health care
payer is prepared to pay to gain a
QALY. The value of a QALY was set
at value of 2× GDP per capita.
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